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ABSTRACT 
Stereotactic body radiation therapy (SBRT) has been assessed by both retrospective and 
prospective studies showing excellent treatment outcome with acceptable toxicity and high 
grade of local control. However, late presenting effects as well as further evaluating toxic 
effects in relation to dose-volume parameters at high-fraction doses and clinical 
characteristics is of the utmost importance in order to further develop the clinical application 
of this method.  
Study I is a retrospective study of 29 patients (32 lesions) who were treated between 1994 
and 2004 with reirradiation with SBRT of a previously treated SBRT-lung target. 
Reirradiation was defined as >50% overlap of the previously treated target. The primary aim 
was to evaluate toxicity. Serious toxicity was scored in 11 patients, with the toxic effects 
being lethal for three patients. Noted risk factors for serious toxicity were central location, 
large CTV and shorter time between the first treatment and the reirradiation. As concluded 
from the analysis, reirradiation of a peripherally located lung target is feasible, whereas 
careful consideration should be taken before reirradiating a centrally located target.  
In study II, we reported on an extended follow-up of a prospectively collected patient cohort 
with medically inoperable stage I non-small cell lung cancer (NSCLC) treated curatively with 
SBRT, 15Gyx3. Between 2003 and 2005, 57 patients were included in this study. Long-term 
follow-up aimed to evaluate late presenting (def. >36 months) effects and toxicity. Five-year-
local control and overall survival were 79% and 30% respectively. Three patients had late 
presenting grade 3 toxicity possibly attributed to their treatment. In conclusion, long-term 
results of SBRT are excellent and support the further use of SBRT for medically inoperable 
cases, the shorter survival however, is a limitation, possibly hiding late presenting effects. 
Study III is a retrospective study of SBRT-treated adrenal metastases, whose objective was 
an evaluation of local control and toxicity. Fifty-eight patients with 62 adrenal metastases 
from various origins were treated between 1999 and 2013 and are included in this analysis. 
The median prescribed BED10 was 80Gy (24-113). Two-year local control rate (based on 60 
evaluable tumors) was 87% and grade 3-4 toxicity occurred in 12% of the patients, the 
majority emanating from gastrointestinal organs. Treating adrenal metastases could render a 
high grade of local control, which has to be balanced against the risk of toxicity. The clinical 
challenge is to select the patients truly benefiting from the treatment with disease control and 
long-term survival.  
In study IV, 57 patients with 61 SBRT-treated apically located lung tumors, defined as the 
center of the tumor located above the aortic arch, were retrospectively collected. Here the 
primary aim was to evaluate radiation induced brachial plexopathy (RIBP). Seven patients 
presented grade 2-3 RIBP; 3 suffering from sensory/motor deficit and 4 from isolated pain. A 
normal tissue complication probability (NTCP) model was fitted to the data, the BED3,max 
NTCP-model did show the best fit. As concluded from this analysis, the brachial plexus has 
to be considered as a risk organ and a dose-constraint of Dmax ≤30Gy to the plexus for a three-
fraction treatment may be advisable.  
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1 INTRODUCTION 
Stereotactic Body Radiation Thearpy (SBRT) is a radiation treatment technique, delivering 
ablative doses to the tumor with very high precision while minimizing the dose to the 
surrounding normal tissue. This method has spread throughout the world, presenting local 
control rates of >90% and limited side effects. SBRT is today the standard treatment for 
patients with medically inoperable stage I non-small cell lung cancer (NSCLC) and is also 
being used widely in the metastatic setting for various metastatic sites and histologies.  
SBRT was developed in the 1990s and towards the end of that decade retrospective analyses 
in Sweden1 and Japan2  have presented promising results for this technique. The analyses 
were however compromised with the limitations of retrospective studies as well as limitations 
of heterogeneity of the patient materials and different treatment techniques in use at the 
various centers. Thus, there was a need for further evaluation of the method to gain 
scientifically higher levels of evidence. Another issue was the radio-biologically founded 
hesitation for adapting the method with respect to late presenting toxicity from large-fraction 
doses. Prospective trials were designed to properly evaluate treatment related toxicity and 
tumor effects; one of the first being a dose-escalation study3 conducted in USA by one of the 
pioneers of this method, Robert Timmerman. This dose escalation study, had delivered 
extremely high biological doses with acceptable toxicity, which formed the basis for further 
trials, aiming to evaluate toxicity and efficacy4. It soon became apparent that SBRT of 
peripherally located tumors gained further support whereas treating centrally located lung 
tumors was afflicted with risk4. In 2008 and 2009 the Nordic SBRT-study group published 
the clinical results from one of the first phase II trials on the method for stage I NSCLC5,6. 
The results from this trial have been of utmost importance in establishing this method in order 
to treat early stage NSCLC and a long-term follow-up of the included patients is presented in 
this thesis.  
Although SBRT has both few and mildly reported side effects, data is limited on dose 
tolerance levels for risk organs using these high fractions doses. Many of the commonly used 
dose constraints in SBRT are direct extrapolations from conventionally fractionated 
radiotherapy (CFRT) and uncertainty prevails whether these constraints are valid for high-
fraction-regimens. Thoroughly addressing toxicity from SBRT-treatments and correlate the 
presented symptoms to dose-volumetric and clinical data is of major importance to further 
develop the clinical implications of the technique. This thesis, with focus on toxic effects of 
SBRT, addresses toxicity in the reirradiation setting (study I), in the setting of SBRT of 
adrenal metastases (study III) and in the setting of apically located lung lesions focusing on 
radiation induced brachial plexopathy (study IV). It also presents an analysis of long-term 
effects of SBRT (study II), with long-term follow-up of a prospectively collected patient 
cohort. 
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1.1 STEREOTACTIC BODY RADIATION THERAPY 
1.1.1 Basic principles 
Stereotactic Body Radiation Therapy (SBRT) was developed at Karolinska University 
Hospital in the 1990s with the radiosurgical concept used in gamma-knife treatment as a 
prototype. The principles of radiosurgery were developed in the 1950s by the neurosurgeon 
Lars Leksell who constructed a frame-based method to treat intracranial lesions 
stereotactically with high-single fraction absorbed doses. Inspired by the results of the 
gamma-knife, the pioneering work of the physician Henrik Blomgren and physicist Ingmar 
Lax led to the invention of extra-cranial stereotactic radiation therapy. One of the obstacles 
for applying high-precision radiotherapy outside the scull was intra-corporal motion of the 
target, a dilemma that was overcome with the invention of the stereotactic body frame (SBF). 
In the SBF, the patient is immobilized in a rigid position, minimizing tumor movement and 
allowing for tumor positioning in a 3-D-coordinate system7 (fig 1.3). SBRT was first tested 
on heavily metastasized patients with few treatment options, but its promising results1 led to 
the broadening of the indications, eventually resulting in a major improvement in cancer 
therapy for patients with medically inoperable early stage NSCLC who now could be offered 
a treatment with a higher chance of a cure. 
The basic principles of SBRT are presented in figure 1.1-1.4. 
 
Figure 1: Basic principles of SBRT; 1) The target is localized in a 3-D-coordinate system; 2)Prior to 
treatment, the tumor position is verified by a verification-CT; 3) The patient is immobilized in the SBF 
+/- abdominal compression to reduce tumor motions, 4)The dose is prescribed to the 67% iso-dose 
line encompassing the PTV, resulting in a heterogeneous dose distribution within the target with the 
central parts of the target receiving  ̴150% of the prescribed dose, 5) Hypofractionation with a few 
high-fraction doses resulting in biological equivalent doses (BED) of >100 Gy. (By permission of 
Ingmar Lax). 
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1.1.2 The SBRT-technique from the 1990s till today 
The fundamental principles of SBRT are shown in figure 1.1-1.4. Practically, before the dose-
planning-CT, the patient is fixed with the arms positioned above the head in the SBF with a 
vacuum-pillow and abdominal compression if the tumor movements are large. The dose-
planning-CT is then performed and used for the delineation of the target and relevant risk 
organs (OAR). The clinical target volume (CTV) comprises the gross tumor volume (GTV) 
with its diffuse growth at the borders. The planning target volume (PTV) is then created by 
adding a margin of 5-10 mm to the CTV to account for set-up-errors and breathing motions. 
The dose is prescribed to about the 67% isodose line encompassing the periphery of the PTV. 
This creates an inhomogeneous dose distribution with the central parts of the target receiving 
approximately 150% of the prescribed dose and a rapid dose-fall-off outside the target thus 
minimizing its dose to normal tissue. The treatment is usually delivered with 6 MV energy 
that use 5-10 coplanar beams and render a very sharp dose-gradient in the longitudinal plane.  
 
Table I Development of SBRT over time at Karolinska University Hospital 
Characteristics 1991-2009 ≥2009 
Prescription isodose (%) ̴ 67%  
Fixation Stereotactic body frame  
Dose delivery Static beams Static beams/VMAT (2011) 
Photon energy 6 MV  
No. of beams 5-7 beams 5-7 beams/2-4 arcs 
Geometrical verification CT-verification CBCT (2009) 
CTV (definition) Tumor  
Tumor margin  Long ≥10mm Trans ≥5mm 
Individual if large breathing 
amplitudes 
Tumor movement assessment Diaphragm/tumor movement w. fluoroscopy 
Tumor movement w. 4D-
CT (2011) 
VMAT: volumetric modulated arc therapy. CBCT: cone-beam computer tomography. 4D-CT: four-
dimensional CT. MV: mega volt.  
More recently, along with technical advances in radiotherapy and imaging, the SBRT-method 
has been refined (table I). Initially, tumor motion during the breathing cycle was assessed by 
fluoroscopy whereas a 4D-CT scan performed at dose-planning has been in-use since 2011. 
This allows for a more accurate estimation of tumor movement and the possibility to create 
individual margins for patients with large breathing motions. Furthermore, image guidance of 
tumor position with online cone-beam CT (CBCT) directly before each fraction is now 
performed, allowing for correction of the tumor position in three dimensions with the patient 
staying in the treatment position. Moreover, dose-calculation algorithms have improved over 
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time to increase their accuracy of anticipated dose distribution. The introduction of 
volumetric modulated arc therapy (VMAT) in which the dose is delivered while the gantry 
rotates in an arc around the patient at the same time as the multileaf collimator (MLC) are 
modulating the beam configuration and dynamically distribute the dose to the target. VMAT 
treatments (instead of static fields) are above all used for complicated treatments with targets 
in close relation to risk organs and allow a better shaping of the dose distribution, aiming to 
avoid dose to OAR and increase the coverage of dose in the target area. Technique 
improvements at other centers include gating8, tumor tracking8 and the use of an internal 
target volume (ITV)9 to mention a few. Here one clinical question of interest though is to 
what extent the technical progress has led to any improvement in clinical outcomes.  
1.2 EARLY STAGE NSCLC 
Lung cancer is one of the major cancer diagnoses in the world and the number one cancer 
related cause of death. The incidence is about 1.8 million cases per year in the world10 and 
3600 cases per year in Sweden11. In Sweden, 5-year-survival for all stages is approximately 
13-19%11. Unfavorable prognostic factors (apart from tumor stage) are male gender12, high 
age11, history of smoking12 and high performance status (PS)12. Lung cancer is divided in 
small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the latter standing 
for approximately 80% of all cases. Of these patients, ~65% present in an advanced or 
metastasized state already at diagnosis and only ~25% have stage I disease13 and are potential 
candidates for surgery if fit for that. In this thesis early stage NSCLC, defined as stage I, is 
addressed specifically in study II and the following chapter will be a discussion of the basic 
principles of classification, staging, diagnostic work-up and treatment of stage I NSCLC.  
1.2.1 Classification and staging 
NSCLC is histologically classified into a variety of different tumor types, the two most 
common being squamous cell carcinoma (SCC) and adenocarcinoma (ADCA). Both types 
are associated with cigarette smoking14 and more recent data show ADCA has increased 
relatively to SCC15. Special forms of lung cancer, driven by targetable mutations (for 
example in the EGFR-complex or by an EML-ALK-translocation) may also be identified but 
do not alter the treatment for early stage disease.  
Except for histology, lung cancer is staged according to the TNM-system which outlines the 
extent of the disease; T describing the primary tumor, N the lymph nodes and M the 
occurrence of distant metastases. The TNM-classification16 is the basis for further classifying 
the disease into a stage between I-IV. Stage I comprise tumors ≤50mm with no nodal 
involvement or distant metastases.  
1.2.2 Diagnostic work-up for early stage NSCLC 
If primary NSCLC is suspected, the patient is referred to the Respiratory medicine clinic, 
which is responsible for the investigation of a suspected lung cancer. The main aims with the 
investigation are to verify the malignancy of the lesion, to determine the extent of the spread 
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of the disease and, in collaboration with oncologists and thoracic surgeons, to determine the 
suitable treatment for the patient.  
First, verification of the malignancy of the lesion is done by bronchoscopy, by which the 
airways are examined visually and by cytological and/or histological sampling. Trans-
thoracic needle biopsy may also give cytological/histological confirmation of the suspected 
malignancy but is affected by a risk for iatrogenic pneumothorax. Radiologically, in addition 
to a CT of the thorax and upper abdomen, an 18F-FDG-PET-CT is performed. This 
examination serves to map the extent of the disease and, in cases where there is no 
histopathological verification; a PET-CT in combination with tumor growth over time may 
serve as a diagnostic tool for lung cancer. Second, lymph nodes suspected for metastatic 
involvement may be further examined by fine needle guided endobronchial ultrasound 
(EBUS), fine needle guided esophageal ultrasound (EUS) or mediastinoscopy.  
Apart from verifying the malignancy and the localized stage of the disease, the general status 
of the patient has to be judged before deciding on the proper treatment of the patient. Lung 
cancer mainly affects the elderly and many patients also have had a significant smoking 
history12. Such patients therefore often have further complications from other diseases 
making them unfit for surgery which is the treatment of choice for early stage NSCLC. There 
are various approaches to decide whether or not a patient is fit to undergo surgery, depending 
on praxis in various countries and at a variety of centers. Medically inoperability is often very 
clearly defined in material from the USA for example as described in a large prospective 
RTOG-trial, where standards for inoperability is pretreatment forced expiratory volume in 
one second (FEV1) <40% than predicted; post treatment FEV1<30% than predicted; carbon 
monoxide diffusion capacity (DLCO) <40% than predicted; baseline hypoxemia or 
hypercapnia; severe pulmonary hypertension; diabetes mellitus with end-organ damage; 
severe cerebral, cardiovascular or peripheral vascular disease; or severe chronic heart 
disease17.  
1.2.3 Treatment of early stage NSCLC 
The treatment is decided at a multidisciplinary tumor board conference where 
pneumonologists, thoracic surgeons, oncologists, pathologists, radiologists and nurses 
participate. The standard treatment for early stage NSCLC is surgery, the type and extent of 
surgery depending on the anatomical localization of the tumor. A standard form of treatment 
is lobectomy but sub-lobar resection may also be performed in cases of poor pulmonary 
function or medical impairment. Generally, for stage I NSCLC, 7%18 of the patients relapse 
loco-regionally after surgery and 5-year-overall survival is about 66-75%18,19. This type of 
surgery may however affect the frequency of relapse; in a randomized trial comparing 
lobectomy and sub-lobar resection, loco-regional recurrence occurred in 7% of the patients 
undergoing lobectomy versus 17% of the patients undergoing sub-lobar resection20 and recent 
results from a metaanalysis comparing segmentectomy and lobectomy showed comparable 
rates of local recurrence for the modalities, overall- and recurrence free survival being 
inferior though for patients treated with segmentectomy21. Patients medically unfit to undergo 
  6 
surgical treatment are then referred to radiotherapy, which today is delivered as SBRT. 
Currently adjuvant chemotherapy after surgery is offered to patients with stage II and selected 
cases with stage IB, rendering an absolute gain in overall survival of 5% at 5 years. 
At present, there are no results from randomized trials comparing SBRT and surgery for early 
stage NSCLC, since attempted randomized trials have closed prematurely due to poor patient 
accrual. Reports from observational studies comparing the modalities do exist22-28. In terms of 
local control, SBRT appeared to be superior23 or comparable to sub-lobar resection22,24 
whereas comparison of local or loco-regional control between lobectomy and SBRT has 
shown results favoring either of the methods22,28 or having comparable results25. Patient 
undergoing SBRT are often in poorer health and older as compared to those undergoing 
surgery. Some studies try to overcome this issue by using matched analyses – a method to 
compare two groups in an observational study by creating similar baseline characteristics, 
thereby overcoming bias in the material. Medical impairment and old age have to be taken 
into consideration when evaluating overall survival (OS). Non-matched analyses show 
inferior OS for SBRT-treated patients23,25 whereas analyses matching patients treated with 
surgery and SBRT, show non-statistically significant differences24,26,27. When evaluating 
cancer specific survival (CSS), the methods seem to be comparable23,24,27. 
Regardless of the outcome from the treatments, there are practical differences between the 
methods that should be considered. Surgery might lead to upstaging of the disease leading to 
adjuvant chemotherapy to some of the surgically treated patients25 , which is not the case for 
SBRT-treated patients. The definition of local recurrence often differ in surgical and SBRT-
materials which should be taken into consideration when comparing reports on these 
methods. Lastly, current studies comparing surgery and SBRT show heterogeneity in the 
cohorts both between different SBRT-regimens and the types of surgery22,25-27. 
 
1.3 SBRT IN THE CLINICAL SETTING 
1.3.1 SBRT of medically inoperable early stage NSCLC 
Historically, patients with stage I NSCLC unfit to undergo surgical treatment have been 
referred to conventional radiotherapy, delivered with small fractional doses over several 
weeks and large margins around the tumor. Tumoricidal doses could often not be delivered 
with respect to normal tissue tolerance from OAR in the vicinity. These conditions led to 
decreased rates of local control. Since local control is linked to long-term survival also 
decreased survival was noted with estimated rates at 3 years for OS and CSS of only 
34%±9% and 39%±10% respectively29, clearly inferior to those being reported from surgery. 
A few patients could not be treated at all, due to physical impairment, and were followed-up 
by observation having a dismal prognosis27,30. The technique of SBRT allows small margins 
to normal tissue and the use of a few large-fraction doses, biologically corresponding >150% 
of dose delivered when using CFRT. As concluded from short-term follow-up of SBRT of 
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primary early stage NSCLC, SBRT had a high rate of local control, limited side effects and 
was convenient for patients. Survival has, however, been limited, probably due to a negative 
selection bias of patients with inter-current diseases. This technique today is standard 
treatment for medically inoperable early stage NSCLC 31.  
Outcome of SBRT of medically inoperable NSCLC addressed in prospective trials6,32-34 and 
in large registry based analyses35,36 has shown local control, regional control and distant 
control rates of 88-92%,86-91% and 79-87% respectively at 3-5 years6,32,35,36 (table II). 
However, data on long-term follow-up is scarce, partly because the technique is young, partly 
because OS i.e. including all causes of death is low. In comparison to the results after surgery 
and conventionally fractionated radiotherapy, SBRT is a viable option for medically 
inoperable patients24,27, but further evaluation with long-term follow-up is of utmost 
importance to understand the occurrence of late presenting effects such as late presenting 
toxicity and relapses.  
 
Table II Overview of results from prospective trials and large cohort studies 
Study Pts Median-FU LC OS/ CSS Toxicity ≥ G3 
 n months/yrs rate rate % of the pts 
Prospective studies  
Fakiris  
200932 70 50 
88% 
(3yrs) 
43%/82% 
(3 yrs) 16% 
Timmerman 
201434 55 
4 
(yrs) 
93% 
(5 yrs) 
40%/N.S 
(5 yrs) 31% 
Matsuo  
201037 101 31 
87% 
(5 yrs) 
47%/N.S 
(5 yrs) 
3% ≥ G3 
pneumonitis 
Baumann 
20096* 57 35 
92% 
(3 yrs) 
60%/88% 
(3yrs) 30% 
Large cohort studies  
Senthi  
201236 676 33 
89% 
(5 yrs) 
<40%/>60%** 
(5 yrs) N.S 
Grills 
201235 483 
1.3 
yrs 
91% 
3 yrs 
48%/77% 
(3 yrs) 
2% ≥ G3 
pneumonitis 
FU: follow-up. LC: local control. OS: overall survival. CSS: cancer specific survival. G3: grade 3. 
N.S not stipulated. * Patient cohort in study II in this thesis.** As measured from the KM-graph 
Conditions for evaluating the late effects of SBRT are at this time unfavorable; patients in 
retrospective material may have a long follow-up38-40 but the material is often compromised 
with limitations such as different dose fractionation schedules, the possibility of both under- 
and over reporting of toxicity and heterogeneity within the patient cohorts. Japanese studies 
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often have a long follow-up, but have included a high number of operable patients and use 
iso-center dosage39,41 making comparison to this study’s material difficult. The RTOG 0236 
study, a phase II study treating medically inoperable NSCLC with SBRT, recently updated 
their results after a median follow-up of 4.0 years and showed high local control, minimal late 
presenting toxicity but, surprisingly, 20% of loco-lobar recurrence34. 
There is limited knowledge on the frequency of late local failures as well as on which types 
of tumors relapse locally after several years and the underlying biological mechanism. Two 
reports41,42 have noted that late local relapses have evolved from small tumors which is an 
interesting finding, since large tumor size otherwise is considered a risk factor for local 
relapse. Tumor tissue samples are of utmost importance to evaluate tumor characteristics, but 
unfortunately, patients with NSCLC often have a significant history of smoking causing 
reduced pulmonary capacity, which might exclude them from invasive diagnosis 
(transthoracic biopsy) due to the risk of pneumothorax. In the absence of a tissue sample, the 
cancer diagnosis is based solely on radiological examinations. From a diagnostic point of 
view, even though histo-pathological verification of the lesion is important, the risk of 
treating a benign lung lesion is less than 5% given radiological signs of malignancy and 
positive 18F-FDG-uptake on PET, as concluded from Dutch research 43. From a research 
perspective or in the setting of a new lesion or suspicion of recurrence, however, there was a 
substantial lack of specific information. An equally important and sometimes complicated 
matter is the diagnosis of a suspected local relapse. If a local relapse is suspected and the 
patient is excluded from lung biopsy due to poor pulmonary function, both high-risk-CT-
features44 and PET-CT45 are non-invasive methods with >90% sensitivity and specificity for 
detecting a local relapse, remain limited here as well the lack of tissue material for further 
analyses of tumor characteristics.  
When avoiding and assessing out-of-field failures (failures outside the irradiated field) it is 
important to divide such occurrences into two different categories; proper staging of the 
disease prior to primary curative treatment and proper diagnosis of a suspected recurrence. 
Patterns of failure, after SBRT of early stage NSCLC, were thoroughly analyzed in a large 
cohort study36. In this analysis, regional control rate at 2 and 5 years were 92.2% and 87.3% 
respectively and the median time to regional recurrence was 13.1 months. From this same 
study, distant control rate at 2 and 5 years were 85.3% and 80.1% respectively and the 
median time to distant recurrence was 9.6 months. Systemic failure is probably partly 
explained by the under diagnosis of occult systemic disease already present at diagnosis. 
PET-CT discovered small metastatic lesions in lymph nodes and in other organs, thereby an 
improved accuracy in staging 43 which is important for deciding on proper treatment. During 
follow-up, suspected out-of-field failures need proper diagnostic evaluation. However, if a 
suspected lesion appears in the lung, there might be an uncertainty if this is a new primary 
lung cancer, occurring in 7-8% of the patients in follow-up in surgical material18,46, or a 
relapse from the previously irradiated lung cancer.  
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1.3.2 SBRT in the treatment of metastases 
1.3.2.1 The oligometastatic state 
Patients with spread disease are generally not candidates for curative treatment and receive 
radiotherapy and systemic treatment with palliative intent to prolong life and reduce cancer 
morbidity symptoms. However here, SBRT has evolved as a treatment modality and may be 
used in selected cases with metastatic disease such as after mixed response to systemic 
therapy, metastases threatening vital organ functions and in the oligometastatic setting. In 
1995 the oligometastatic state was proposed by Hellman and Weichselbaum47, describing a 
state where the metastases are limited in number and location. Although often referred to as 
maximum five metastatic lesions, the oligometastatic state is not bound to a certain number of 
lesions and one might also consider that the number of organ systems affected by metastatic 
disease could be of major importance.  
In the oligometastatic state, systemic therapy for microscopic disease in combination with 
aggressive local treatment of the metastases may render improved outcome with control of 
the cancer and longtime survivorship, a current hypothesis being investigated in ongoing 
prospective trials. Metastasectomy of oligometastatic colorectal cancer in the liver and lung is 
used regularly in the clinic and conceptually concordant, one might consider SBRT in order 
to completely eradicate all macroscopic tumor lesions in an oligometastatic situation. 
Favorable outcomes have been reported after both surgical treatment48,49 and SBRT of 
oligometastatic disease49-51. An upcoming challenge for oncology is how to pick out the 
patients with true oligometastatic disease who will benefit the most from the use of SBRT to 
eradicate visible oligometastatic disease.  
1.3.2.2 Lung and liver metastases 
To better understand the side effects that could develop post SBRT there is a need to describe 
the basic anatomy of the organs and the definitions used in SBRT and their background. 
Traditionally in SBRT, a lung target is categorized as being either peripherally or centrally 
located. The central location has historically been set to reside within or touching a 2-cm-
zone around the proximal bronchial tree (the carina, the main bronchi, the intermedius 
bronchus and the lobar bronchi)4, over time occasionally adding a zone around the 
mediastinal structures as well. At Karolinska since 2011, this definition has been tightened up 
to within 1 cm of the proximal bronchial tree. The peripherally located tumors are outside the 
1- or 2-cm-zone and the centrally located lesions are within the zone or touching it from 
outside. Centrally located tumors are likely to be in the vicinity of radiation sensitive OAR 
such as the bronchi, the esophagus and the heart, from which severe side effects may possibly 
develop.  
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Figure 2: The two dose planning pictures show a typical peripherally located tumor (left) and a 
typically centrally located tumor (right). 
From a side effect point of view, both the liver and the peripheral parts of the lungs are 
tissues with “parallel organization” which mean that they are constructed by functional 
subunits (FSU) (ex alveoli/capillary in the peripheral lung) that work independently to 
perform their function. This is to be compared to a serially functioning tissue (ex spinal cord) 
where the FSU work together to perform their task. Radiotherapy induced toxic effects in 
parallel functioning organs are typically related to the irradiated volume of the organ whereas 
serially functioning tissue is more susceptible to high maximum doses, sometimes to a 
minimal volume. Radiation induced harm to the periphery of the lung will leave the rest of 
the lung intact and functional whereas a too high dose to the spinal cord will cause loss of all 
function distal to the injury. From this thesis, toxicity to parallel functional tissue is addressed 
above all for lung (study I, II, IV) and toxicity to serially functional tissue is addressed 
specifically for the plexus and to some extent the gastrointestinal tract (study III, IV). 
Metastatic disease in the lung and liver is common and these organs constitute the two organs 
most often treated with SBRT. Primary tumors that often metastasize to the lung include lung 
-, colorectal -, renal-, breast cancer and sarcoma and correspondingly, liver metastases are 
common in colorectal -, breast- and lung cancer as well as in other primaries. SBRT has been 
used successfully in treating lung metastases from a variety of primary tumors52 including 
traditionally radiotherapy resistant tumors with low α/β-values such as renal cell carcinoma 53 
and sarcoma 54. With the exception of colorectal cancer metastases, which traditionally are 
treated with even higher doses (17Gyx3 prescribed to about the 67% isodose line at 
Karolinska for colorectal metastases), all tumors are treated with the same fractionation 
schedule regardless of primary origin and histology. Liver metastases have also been 
successfully treated with local control rates of >90% at one and two years respectively and 
with limited toxicity55,56.  
1.3.2.3 Adrenal metastases 
Adrenal gland metastases are being specifically addressed in this thesis in paper III and to 
understand the consequences of SBRT and how to interpret the results in paper III, the basic 
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anatomy and physiology of the adrenals as well as the diagnostic work up for adrenal 
metastases are described.  
 The adrenal glands are paired organs, situated anterio-superior and slightly medial to the 
upper part of the kidney. They are enclosed by a fibrous capsule and a cushion of fat that lie 
on top of each kidney, encapsulated by perirenal fascia from which they are connected to the 
diaphragm. The adrenal glands have rich blood supply from the superior, middle and inferior 
suprarenal arteries, which derive from the inferior phrenic artery, the abdominal aorta and 
from the renal artery respectively. They drain in the suprarenal vein and the lymphatic 
drainage pass to the lumbar lymph nodes57. The rich blood supply then renders them 
susceptible to metastatic disease, especially breast cancer 58, lung cancer 58,59 and cancer from 
the stomach 58,59.  
Adrenal masses discovered accidently at routine radiologic examinations – incidentalomas – 
are also common with an incidence of approximately 5% in the population going through 
imaging, 2-3% of those being malignant60. However, in a cohort of patients with ongoing 
cancer an accidently discovered lesion is malignant in ̴ 50% of the cases61 which demands for 
accurate diagnosis and in a patient with a known neoplasm, an adrenal mass should always be 
suspected for metastasis unless definitive diagnosis of a benign lesion is possible62. The 
radiological diagnostic work-up of suspected adrenal metastases, often initiate with 
controlling the size of the lesion and whether it has grown over time (likely for malignancy). 
Second, a non-enhanced CT followed by washout studies is performed where attenuation 
values >10 HU and delayed washout suggest malignancy. Further investigations include 
MRI, showing low T1- and increased T2-signal with progressive enhancement for 
malignancy, and PET-CT, showing high SUV-value for malignancy60,62. Image-guided 
adrenal biopsy is an invasive method yet has a diagnostic accuracy of 96% and has a low 
probability of complications63.  
Adrenal metastases are often clinically silent, only about 4% of the patients present 
symptoms59, such as pain, adrenal insufficiency and peritoneal hemorrhage being most 
frequent. CFRT with doses of 1.7-3.0 Gy per fraction up till total doses of 29-45Gy, reduce 
pain symptoms with an approximately 75% response rate64.  
The treatment of adrenal metastases is based on the extent of tumor burden and the patient´s 
general condition. The local treatment of choice is surgery which has 1-year local control 
rates of 77-93% dependent on tumor size 65, when bearing in mind the potential selection bias 
of healthier patients with favorable tumor biology in surgical materials. Complication rates 
depend on surgical technique and ranges between 4-34% for all complications and 0-11% for 
major complications 65. If technically possible, surgery can be performed with laparoscopic 
technique 66, reducing the operative time, the lengths of hospital stay, the estimated blood loss 
and the overall complications 65.  
SBRT of adrenal metastases have shown a wide range of local control between 55-100% 67-76 
and mild side effects, only two reports specifically addressing adrenal metastases describe 
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grade 3 events (nausea, hematologic toxicity76) and gastric ulcer (grade 2) 72. Four reports 
describe local control of 82-100%67,68,71,76 being comparable to other SBRT treatment sites 
and to surgery. However, the investigated patient cohorts are small and the follow-up is 
limited to less than 1.5 years (Table III), potentially hiding local recurrences and limiting the 
interpretation possibilities. 
 
Table III Analyses of SBRT-adrenals showing high local control rates 
Study No of pts SBRT Median-FU LC Time to LF 
 n Gy/fractions m rate m 
Cassamassima 
201268 48 36/#3* 16.2 
 90%  
(2 yrs) 4.9 
Ahmed  
201367 13 33.75-60/#5 OS 7.2 100% 
- 
Katoh  
200871 9 48Gy/#8**  16 
100%   
(1 yr) 
- 
Li  
201376 
26 30-50Gy/#3-5 OS 17 82%/100%§ N.S 
 FU: follow-up. LC: local control. LF: local failure. N.S: not stipulated. OS: overall survival. 
*prescribed dose to the majority of the patients. **prescribed to all but one patient.§82% for patients 
with prescribed doses <100Gy (BED10) and 100% for patients with prescribed doses≥100Gy (BED10). 
 
Given the success of local treatment of adrenal metastases, the question in this situation 
remains: which patients should be treated. Single adrenal metastasis from NSCLC is a special 
entity, and treatment with surgery for these patients has reported beneficial outcome with 5-
year-overall survival rates of 25%-34% 77,78, favoring adrenal gland metastases ipsilateral to 
the primary tumor  and node negative disease78. The underlying mechanism may be a 
lymphatic spread through direct lymphatic communication between the lung and the 
abdomen79, mimicking a regional extension of the disease. One criticism of this theory is that 
a single metastatic spread may also reflect less aggressive tumor biology, regardless of 
treatment of the metastasis80. SBRT with curative intent for isolated adrenal metastasis from 
NSCLC has been reported in only two analyses70,72 and although the patient cohorts are small 
with 8-13 patients, the outcome is favorable among long-term survivors72 and median 
progression free survival of 12 months70, respectively. Another report comparing SBRT and 
adrenalectomy for patients with different primary tumors and single adrenal metastases 
showed comparable overall survival rates at one year of 62% and 77% respectively (p>0.05), 
suggestive for SBRT to be a non-invasive alternative to surgery for isolated adrenal 
metastases81.  
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1.4 TOXIC EFFECTS OF SBRT 
The clinical success of SBRT has brought about a desire from clinicians to treat targets in 
radiotherapy-technically complicated situations with SBRT and to combine ablative 
radiotherapy with systemic treatment, not just aiming for local control, but also to increase 
survival rates even in metastatic patients. Although SBRT has few and mildly reported side 
effects, there is limited data on tolerance levels of radiation for OAR using these high fraction 
doses. Many of the commonly used dose constraints as well as the concept of risk-adapted 
therapy are direct extrapolations from CFRT and one remains uncertain, if such assumptions 
and constraints are valid for high-fraction-regimens. Thoroughly addressing toxicity from 
SBRT-treatments and correlate the presented symptoms to dose-volumetric and clinical data 
is of crucial importance to further develop the clinical implications of the technique. 
Generally, the clinical impression of treatment related toxicity of SBRT of peripherally 
located lung lesions, is that the most common side effects are mild and transient and consist 
of skin rash, fibrosis in the high-dose area and a related cough. The Nordic phase II trial of 
SBRT treated NSCLC reported grade 1-2 pneumonitis 18% 5 grade 1-2 dyspnea 18% 5 and 
grade 1-2 fibrosis 35% 5.  Serious toxicity (grade 3-4) in prospective trials have been reported 
in the range of 16-30% 5,6,32 and mainly consisted of pulmonary related symptoms, with the 
majority presenting within the first year post treatment5. A higher rate of serious toxicity has 
been noted with centrally located lesions and the apical part of the lung is another area that 
needs to be approached with caution, when taking into consideration the brachial plexus 
which may be at risk for highly absorbed doses. 
1.4.1 Pneumonitis and fibrosis 
Symptomatic pneumonitis is a clinical condition marked by dyspnea, cough, fever and 
thoracic pain. To assess risk of radiation pneumonitis a commonly used dosimetric parameter 
is V2082, which describes the percentage of the lung volume receiving 20Gy or more. In the 
everyday clinic during radiochemotherapy with CFRT for locally advanced NSCLC, V20 is to 
be kept <35% to reduce the risk of pneumonitis. After CFRT, the symptoms usually start 
within the first few weeks after radiotherapy completion. The pathophysiology of the 
condition is believed to be caused by an inflammation in the alveoli of the lung and the 
histological findings of the acute phase comprise edema in the alveolar septae and 
hyperplasia of the alveolar lining cells as well as in increase of alveolar macrophages and 
fibroblasts 83. The incidence of symptomatic radiation pneumonitis post SBRT range from 9-
20%, presenting after a median time of 3-5 months84-87, but may appear as late as 16 months 
post treatment85. The radiological signs of severe pneumonitis as presented earlier when 
compared to mild pneumonitis88. There is an inconsistency in the reports on risk factors, 
different analyses reporting dose-volumetric risk factor such as MLD89 84,86,87, V589, V10  
89,90, V20 86,87, V25 85, and PTV 85,91. However, in a large analysis of 483 patients (7% 
experiencing ≥ grade 2 pneumonitis), no dose-volume related risk factors were significant 
predictors for pneumonitis ≥grade 235 and similarly, in an analysis of 236 patients, 12% 
developing symptomatic pneumonitis, no dosimetric factor was predictive in multivariate 
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analysis although clinical risk factors of female gender, pack-years of smoking and larger 
IGTV and PTV were 91. Considering these large discrepancies between these analyses, there 
were no certain dose-volume parameters that could be used for predicting the incidence of 
lung toxicity. Thus the contention here would be the individually important elements with 
regard to pneumonitis.  
Another aspect of radiation induced lung injury is whether patients with decreased pulmonary 
function are at greater risk for pneumonitis when compared to patients with normal lung 
function. The first report on the patient material in study II did not show an increased risk for 
radiation pneumonitis for patients with severe COPD versus patients with cardiovascular 
disease5. Patients with severe COPD might even have a reduced risk for radiation 
pneumonitis as compared to patients with milder COPD 92, possibly explained by the “tissue 
amount” theory, claiming that patients with severe COPD have less lung tissue to generate an 
inflammatory response and thus have a lower risk of pneumonitis. There is further support 
here that there is a known increased risk for radiation pneumonitis in patients with 
radiological signs of interstitial lung disease 93 as well as from an analysis comprising the 
highest rate of pneumonitis included approximately 30% operable patients 85.  
Radiation induced fibrosis is a dose/volume related condition characterized by fibrotic 
changes in the high dose region, radiologically presented as dense consolidation and 
retraction of pulmonary tissue 94 (Fig 3). Fibrosis is a dynamic process starting at 6-12 
months post treatment with remodeling that continues on for several years94. The radiological 
characteristics are seen in up to 100% of the patients 95, only a few cases being symptomatic 
though6,38,95. 
 
 
Figure 3: Pneumonitis approximately 5 months post SBRT (left picture) and fibrosis (right picture).  
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1.4.2 Chest wall toxicity and rib fractures 
Treating lung tumors located adherent to or close to the rib cage may result in highly 
absorbed doses to the chest wall and to the ribs, causing chest wall toxicity with thoracic pain 
and rib fractures. From its earliest onset, thoracic pain is often transient and can be treated 
with corticosteroids, whereas any suffering recurring pain responded poorly to pain 
medication. Improvement of pain symptoms may be seen after a median of 4-6 months 96,97. 
Prospective trials and the growth in clinical experience have drawn attention to these 
morbidity symptoms and both thoracic pain and rib fractures have then been addressed in 
specific analyses, aiming at evaluating the clinical development as well as both the dose-
volumetric and clinical risk factors. Chest wall pain, often developing at a median of 7-9 
months post treatment 96-98, occur in a frequency of 11-42% (all grades) 96-100 and 13-32% 
(≥grade 2)96-98  either isolated or in combination with rib fractures. Rib fractures, generally 
appear later after approximately 2 years 97,99 and are somewhat less common, reported 
frequencies ranging between 1.6-23%96,97,99-101, the highest numbers representing both 
symptomatic and non-symptomatic fractures 101. Interestingly, radiological findings of chest 
wall edema, thinning of the cortex and osteosclerosis have been correlated with, and tending 
to precede rib fractures 102. Clinical and tumor related risk factors for chest wall pain and/or 
rib fractures include female gender 101,103, small tumor-chest wall distance 99,101, large PTV 
98,99, high BMI100,104 especially for diabetics 100 and both young age 99 and old age have been 
reported, the latter for radiation induced bone injury 103.  
Dose tolerance limits for the chest wall are currently not well known. Based on the performed 
analyses comprehensive dose constraints are hard to establish due to the heterogeneity in the 
patient materials with different fractionation schedules, the different delineation techniques of 
the chest wall and the different clinical findings. However, for a 3-5 fraction treatment V30Gy 
96-98,100 seems important and may be restricted to 30cc 96 or 70 cc 97, although in addition to 
dosimetric variables, clinical characteristics are also a required consideration 100,103. Risk 
adapted fractionation schedules with five or ten fractions have also been suggested, with low 
reported toxicity of chest wall pain ≤12% and rib fractures <2% 99,105. Currently at 
Karolinska, tumors are treated in the vicinity of the chest wall with 3-8 fractions, limiting the 
dose to the chest wall for a three-fraction-treatment to V30Gy<70 cc.  
 
1.4.3 General pulmonary toxicity 
The interpretation, especially in retrospective material, of side effects of general character 
such as dyspnea, cough, fatigue, COPD-exacerbation and pneumonia, is influenced by 
considerable uncertainties as to whether the symptom is attributed to the treatment or the 
intercurrent disease. Patients with medically inoperable NSCLC, often due to COPD or 
cardiovascular disease (CVD), diagnosis has shown already to suffer from respiratory 
symptoms. Dyspnea, cough and COPD-exacerbations are parts of the picture of COPD. In 
prospective trials these symptoms have occurred in a clinically acceptable frequency and 
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grade and dose-volumetric parameters have not been coupled to the aggravation of dyspnea 
post treatment106. 
When assessing a patient for risk of developing radiation induced side effects, traditionally 
Normal Tissue Complication Probability Models (NTCP-models) estimating the risk of 
developing a side effect in relation to dose to the OAR, have been used. The NTCP-models 
are based on dosimetric data from the dose-volume histograms and on toxicity. The 
probability of developing the side effect may then be estimated from the model (The creation 
of a NTCP-model is described in section 2.4 Analyses, Material and Methods). The 
traditional NTCP-models, however, do not consider patient related factors, such as 
performance status, lung function, smoking status, other treatments, the patient’s general 
condition and the individual radio-sensitivity, which might be of major importance. 
Mathematical modeling, using machine learning systems on large data sets, where both 
patient characteristics and dose-volumetric features are included, which are being developed 
in order to help foresee toxicity like dyspnea107.  
 
1.4.4 Pulmonary function changes 
An interesting aspect of radiation-induced toxicity is the possible decline in pulmonary 
function capacity over time as measured by pulmonary function tests (PFT). The most 
commonly evaluated parameters in this setting are FEV1, FEV1% and DLCO. From the first 
report on the material presented in study II presented in this thesis, no decline in FEV1% 
could be established for the cohort at a median time of 14 months post SBRT 5.  
Results from pulmonary function tests post SBRT are diverse, with reports of small, yet 
statistically significant decreases in PFTs over time 108,109 and DLCO 110 respectively, as well 
as reports showing no statistically confirmed changes 111-114, two of them being long-term 
follow-up with 3-year-data, unfortunately based on only having very few patients 111,112. A 
dose-effect relationship for pulmonary function changes has not been proven109. Notably, 
when interpreting these results, progressive decline in lung function over time can be 
expected for patients affected by COPD, causing interpretation difficulties as to whether the 
decline is treatment related or caused by the underlying COPD.  
A very important aspect is, given a low pretreatment pulmonary function, an elevated risk for 
pulmonary toxicity 108,110,113 or inferior overall survival 110,113,114 could not be confirmed in the 
majority of analyses and therefore poor pulmonary function alone should not exclude patients 
from SBRT.  
1.4.5 Cardiac and large vessel toxicity 
Radiation therapy may damage the heart in many ways, causing pericardial and myocardial 
disease as well as valvular damage and injuries to the conduction system115. Cardiac toxicity 
post SBRT is reported in low incidences, primarily in the form of heart failure grade 1-3, 
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cardiovascular disease grade 1-2, arrhythmia grade 1-2 and non-symptomatic pericardial 
effusion 6,17,116,117. Certainly, there is a substantial possibility of underreporting of cardiac side 
effects, partly due to the high incidence of both arrhythmias and cardiovascular disease in 
general, partly due to a possible misinterpretation of symptoms such as dyspnea as a result of 
subclinical heart failure. In assessing dose to the heart, we normally delineate the heart as one 
homogenous mass and do not consider which functionally different parts of the heart are at 
greatest risk for radiation induced injury and what dose-volume parameter that part of the 
heart might be more sensitive to. 
 The large vessels in the mediastinum are another OAR, which might be at risk during 
radiation therapy; dependent upon the target location. Little is known on their tolerance from 
SBRT-regimens, and currently at Karolinska we do not use any restrictions for the great 
vessels in the mediastinum. Of interest here, a recent report from Japan on centrally located 
tumors, compared their clinical outcome of toxicity to the dose constraints defined by the 
University of Texas Medical Center118, and based on the recorded toxicity, suggested that the 
aorta, v cava and pulmonary vein may show a greater tolerance to radiotherapy as compared 
to the pulmonary artery and the bronchus, particularly in the pulmonary hilus119. It remains 
hopeful that this encouraging aspect will be further heightened with the results from the 
RTOG 0813 and the ongoing HILUS-trial, being conducted by the Nordic SBRT-study 
group.  
1.4.6 Central airways toxicity 
Ever since the first report of increased toxicity after SBRT of centrally located lung lesions4, 
uncertainty prevails on just how to treat these lesions with radiotherapy. In a prospectively 
collected cohort of 70 patients, 22 being centrally located and treated with 60-66Gy in three 
fractions depending on tumor size, Timmerman et al reported increasing risk for grade 3-5 
toxicity for centrally located tumors 4. The results were updated in 2009 after a median 
follow-up of 50 months, describing grade 3-5 side effects in the form of apnea (n=1), pleura 
effusion (n=2), decline in pulmonary function tests values (n=2), pneumonia (n=4), 
hemoptysis (n=1) and respiratory failure (n=1). These last three symptoms being deadly for 
five patients32. Also, serious toxicity in form of tracheal necrosis, esophageal ulcers and 
bronchial strictures has also been described in the literature. 
More recent reports have described acceptable toxicity 116,120-124 and local control rates of 
≥85%, given a BED10 of ≥100Gy for centrally located lesions 116,123,124. The largest report 
constitutes a systematic review of 563 lung tumors from 20 different analyses from which the 
authors have concluded that when utilizing appropriate fractionation schedules with BED10 
≥100Gy and BED3≤210Gy, treatment related mortality was <1% and local control ≥85%. 
From the same report, grade 3-4 toxicity was <9% 123. Thus, there is a growing body of 
evidence for safely treating centrally located tumors with SBRT; however data on dose 
constraints for organs at risk remain scarce. Currently, the results from the RTOG 0813-trial, 
a prospective dose escalation phase I/II trial, are pending and patient accrual for the HILUS-
trial, a phase II-trial evaluating local control and toxicity for 7Gyx8 for tumors within 1 cm 
  18 
from the proximal bronchial tree, conducted within the Nordic countries, is almost finalized. 
Data from these prospective trials will be of key importance in the further evaluation of 
SBRT of centrally located lesions.  
The tolerance levels for high-fraction doses of the central airway structures are not very well 
known. Currently at Karolinska, patients with centrally located lesions (within 1 cm from the 
proximal bronchial tree) are treated with 7Gyx8 with dose guidelines of maximum 7Gyx8 
(BED3,max 187Gy) to the ipsilateral bronchus and hard dose constraints of 6.1Gyx8 
(BED3,max 148Gy) to the contralateral main bronchus and trachea. These constraints are based 
on a retrospective analysis from the Nordic SBRT group evaluating bronchial toxicity post 
SBRT with radiation induced atelectasis as surrogate for bronchial toxicity. No atelectasis 
was noted below the corresponding dose of 6.5Gyx8 (BED3 =165Gy)125. Except for dose 
restrictions that can be withdrawn from the DVHs, in the everyday clinic we try to avoid 
irradiating the entire circumference of a main bronchus and not to irradiate any lesion 
reaching through the wall of a main bronchus visible on a CT-scan. 
Another noteworthy characteristic is the possible mechanism and increased risk of toxicity 
for centrally located lesions. The most common type of grade 3-4 toxicity is pneumonitis, 
pneumonia, dyspnea and bronchial strictures whereas the most common toxic deaths have 
been attributed to direct bronchial injury (stenosis/strictures/fistula) and hemoptysis 123. A 
possible explanation for pneumonitis and pneumonia might be that the central airways, as 
opposed to the lung parenchyma, are not sterile. One could further hypothesize that a 
radiation induced minor injury in this situation may be complicated with reduced ventilation 
and bacterial colonization and thus have a reduced chance to heal itself. The bronchi are also 
considered a serially functioning organ where an injury will lead to the disruption of the 
function of the organ distant to the injury. Direct bronchial injury and hemoptysis may reflect 
a serious radiation induced wound; whether healing with a fibrous scar or not healing.  
1.4.7 Radiation induced brachial plexopathy 
1.4.7.1 Brachial plexus 
The brachial plexus is one of the main OAR when treating apically located lung lesions and it 
is important to understand the anatomic definition and the function of the plexus to foresee 
the physical impairment that a lesion causes. The brachial plexus is a complicated structure 
extending from the spinal cord to the axilla. It is formed by the roots exiting C5-T1 (fig 4), 
which form three trunks that pass behind the clavicle and the sternocleidomastoid. The lower 
trunk lies in close proximity to the apex of the lung, being at risk during SBRT-treatment of 
apical lung lesions. Retroclavicularly, the trunks divide into anterior and posterior divisions, 
which form three cords, defined as the posterior, the lateral and the medial, with respect to 
their relation to the axillary artery. The medial cord is an extension of the anterior division of 
the lower trunk and gives rise to the ulnar nerve and the medial head of the median nerve. 
The lateral cord is formed by divisions from the upper and middle trunks and the posterior 
cord is formed by the posterior divisions from all trunks126 .  
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Figure 4: Anatomical description of the brachial plexus. The red marking in the picture describes the 
part of the plexus delineated in study IV. 
As shown above, the plexus is a complicated structure with a complicated physiology where 
the extent of functional impairment following an injury to the structure, will depend on the 
location on the lesion. In SBRT of apically situated lung lesions, the greatest risk for plexus 
injury prevails in the parts running close to the lung structure i. e the lower trunk and the 
cords126.   
1.4.7.2 Radiation induced brachial plexopathy 
Radiation induced brachial plexopathy (RIBP) is a condition characterized by numbness, 
pain, paresthesia and motor deficit in the affected upper extremity. The occurrence of RIBP 
has been reported since the 1960s, mainly in breast cancer treatments. Clinically, the 
symptoms of RIBP after CFRT often present with paresthesia 127-131 (and swelling and 
heaviness of the arm129) later developing into a picture reflecting a complex neural injury 
with symptoms of paresthesia /numbness, pain and motor weakness127,128,132,133. The latency 
period from radiation therapy to the first symptom ranges from immediate onset till 26 years 
post treatment129-135, three series reported a median time of  ≥ 1 year post treatment127,129,131. 
Of interest though, one report has suggested that the initial symptoms may appear earlier with 
higher doses131, a finding which is in line with results from our analysis (Study No. IV in this 
thesis); where all the cases had presented symptoms within 13 months.  
The clinical development of RIBP is in most cases considered progressive and the symptoms 
irreversible, however reports on spontaneous improvement do exist 131,136,137. Objective signs 
of RIBP on clinical examinations include decreased/absent muscle stretch reflexes, 
Modified illustration: Ferrante M; 
Brachial plexopathies: classification, 
causes, and consequences123; Muscle 
Nerve 30: 547–568, 2004, Wiley 
Periodicals, Inc.© 2004 Wiley 
Periodicals, Inc. (By permission) 
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hypestesia/hypalgesia and weakness130,133. Neurophysiological examinations typically reveal 
demyelinating conduction block on motor nerve conduction studies and myokymic discharge 
and fasciculation potentials on needle examination evaluations126,128,133,138. A clinically 
important finding is that patients showing clinical symptoms and signs of RIBP also present 
significant abnormalities on neurophysiologic examinations133, showing that clinical findings 
are concordant with objective neurophysiological findings.  
The theory of the underlying mechanism behind RIBP constitutes of an initial 
microvascular injury and later on radiation induced fibrosis and a direct neurological 
injury137. Radiation induced fibrosis itself is a progressive state, going from chronic 
asymptomatic inflammation to a poorly vascularized phase with retractile fibrosis139. From 
autopsy material, one case with RIBP was recorded with signs of extensive fibrosis whereas 
two patients with fewer or no symptoms had not shown or did show only minimal fibrosis131. 
The long latency period of RIBP may be explained by the “double crush” phenomenon140 
which, although debated141, suggests that a nerve suffering a first minor trauma is more 
susceptible to a second injury or compression. 
1.4.7.3 Dose constraints to the brachial plexus 
Another question is how sensitive the brachial plexus is to radiation therapy and what dose 
guidelines to the brachial plexus should be recommended. Risk factors for RIBP include high 
fraction doses, high total doses, chemotherapy, high or young age just to mention a few137. In 
CFRT there are several reports on RIBP and Emami-data that suggest neurological injury, 
TD5/5 (the probability of 5% complication within 5 years from treatment) of the plexus does 
occur at about 60-62Gy in 1.8-2-Gy fractions142 and current trials for head-and-neck cancer 
conducted within the RTOG had used dose-constraints in the order of 60-66 Gy143. However, 
there have been appeals to increase the dose to the tumor to achieve tumor control that do 
prescribe an increase allowable dose to the plexus area. Eblan and colleagues132 have 
proposed to push the dose constraints (CFRT for radiochemotherapy for lung cancer) to Dmax 
≤78Gy (BED3 130Gy) and V76Gy ≤1cc (BED3 127Gy), with their motivation that the risk of 
RIBP must be weighted against the risk of a sublethal dose to the tumor, leading to local 
failure with tumor growth into the plexus and extensive morbidity symptoms132. In SBRT 
research, there are just three reports specifically addressing this issue116,136,144. A summary of 
the results is shown in table IV. 
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Table IV Summary of studies addressing RIPB post SBRT 
Study Tumors Dose to the plexus RIBP Conclusion – 
new plexus dose 
restriction    n BED3,max V30Gy* Grade & no of pts 
Forquer 
2009136 
RIBP- 30 
84Gy 
(10-851) 
- - Dmax <26 Gy for 
3 or 4 fractions 
RIBP+ 7 123Gy 
(45-839) - 
G2:4;  G3:2; G4:1 
Chang 
2014116 
RIBP - 7** ≤137Gy ≤0.2 cc - Dmax ≤35 Gy and 
V30Gy≤0.2cc for  
4 fractions RIBP+ 3 >137Gy >0.2 cc G2-3: 3 
Doses described to the patients with and without RIBP in two studies addressing RIBP specifically. 
RIBP+: radiation induced brachial plexopathy. RIBP-: no radiation induced brachial plexopathy. 
BED3,max: maximum dose to the plexus in BED3. V30Gy:volume of the plexus receiving ≥30Gy. *Four-
fraction-treatment.**Three additional patients, treated with 10Gyx7 were at risk for RIBP, but did not 
develop RIBP and doses to the brachial plexus were not stipulated.  
1.4.8 Stomach and intestinal toxicity 
Treating target lesions in the abdomen with SBRT could be a delicate matter when delivering 
ablative doses; maintenance of a balance in order to achieve local control while at the same 
time avoiding an over-dosage of the OAR, a possible occurrence in the stomach or intestines. 
An injury to the GI-tract may be present as general symptoms of nausea, vomiting or 
abdominal pain or it may reflect a direct localized injury and present itself as an ulceration, a 
perforation, a stenosis or a bleeding from the injured spot. When treating abdominal targets, 
the parts of the GI-tract frequently at risk are the stomach (treatment of left sided adrenal 
metastases and lymph nodes), the duodenum (treatment of right sided adrenal metastases, 
pancreatic carcinoma especially in the head of the pancreas, liver targets) and the small bowel 
(treatment of adrenal metastases, lymph nodes, pancreatic carcinoma etc).  
Whereas lung toxicity post SBRT of peripherally located lesions often is endurable for the 
patient, gastrointestinal toxicity can be life threatening and require surgical intervention. 
Nausea and vomiting as well as pain are frequently reported side effects after SBRT of 
abdominal targets, the former occurring in a frequency of approximately 38-40% (all grades) 
and the latter in a frequency of 6-30% (≥grade 2)145,146 within 3 145 or 6 months 146. 
Gastrointestinal grade 3 and 4 toxicity presented as ulcers, nausea, diarrhea, perforations, 
bleeding and stenosis within one-year post treatment were the conclusion from three 
analyses146-148. 
Dose constraints to the GI-tract are currently quite unknown concerning high-fraction doses. 
At Karolinska, dose constraints with SBRT are set to EQD2 52Gy to 5 cc (corresponding to 
23.7Gy for three-fractions) of the intestine or stomach, trying to avoid irradiating the entire 
circumference. There are no prescribed maximum dose constraints, the underlying reason 
being unpublished results from our own institution where large irradiated volumes have been 
critical in the development causing severe side effects. Two analyses from Korea have 
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specifically addressed the issue of the dose volume effect and the risk for gastroduodenal 147 
and intestinal toxicity148 post SBRT. In both reports V20-V35 and Dmax were good dosimetric 
predictors of both gastroduodenal and intestinal severe toxicity. Surprisingly though, for 
gastroduodenal toxicity Dmax was the best dosimetric predictor, whereas V25Gy was the best 
dosimetric predictor for intestinal toxicity. In a 3-fraction-treatment, keeping Dmax<35Gy for 
the stomach and duodenum and V25Gy≤20cc to the intestines may reduce the probability of 
severe complications to the respective organs by less than 5%147,148 which is clinically 
acceptable. Apart from these dosimetric considerations, the authors also point out clinical risk 
factors to be any history of a previous ulcer, for gastroduodenal toxicity, and the length of 
treatment time, for intestinal toxicity. Although the authors had presented a large number of 
events relative to other reports, it was noteworthy that both these analyses comprise limited 
patient material which was retrospectively chosen and had excluded nausea as a toxic 
symptom, leading to a possibility of underreporting severe side effects.  In comparison, the 
QUANTEC-report from 2010 suggests somewhat more careful dose constraints; to the 
stomach maximum 22.5Gy to approximately 5 cc or 4% and Dmax<30Gy for a 3-fraction-
treatment; and to the small bowel <30Gy for 3-5 fractions149.  
1.4.9 Adrenal insufficiency 
1.4.9.1 Adrenal gland 
The adrenal glands are composed of cortex (derived from the mesoderm) and medulla 
(derived from neural crest cells) with completely different biological functioning. The cortex 
is composed of two layers; the outer layer (zona glomerulosa) producing aldosterone which 
mainly is regulated by the renin-angiotensine-system and the inner layer (zona 
fasciculata/retiucluaris) producing glucucorticosteroids, androgens and small amounts of 
estrogens and is regulated by the adrenocorticotropic hormone system (ACTH-system)150. 
The adrenal medulla produces epinephrine (80%) and nor-epinephrine and is regulated by the 
sympatic nervous system151. Unlike the cortex, the proper functioning of the medulla is not 
essential to life.  
1.4.9.2 Adrenal insufficiency 
Adrenal insufficiency may then develop when >90% of the adrenal cortex is lost66,150, making 
adrenal insufficiency to be a potentially expected side effect post SBRT. Clinical symptoms 
of adrenal insufficiency are characterized by fatigue, loss of appetite, weight loss, nausea, 
vomiting, abdominal pain, hypotension and hyperpigmentation152. Diagnosis is made from an 
ACTH-stimulation test in which S-cortisol was measured at baseline and at 30min or 60 min 
after parenteral administration of adrenocorticotropic hormone152. To separate primary (non-
functioning adrenal gland) and secondary adrenal insufficiency (disturbance of the 
hypothalamus-pituitary gland axis), ACTH- and renin-levels in the blood may be measured; 
which show increased levels of primary adrenal insufficiency152. Treatment consists of 
substitution of glucocorticoids and a mineral corticoid (with primary adrenal 
insufficiency)150.   
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Current knowledge on the radio-sensitivity of the adrenal glands remains limited. Clinically, 
two reports have described two cases of adrenal insufficiency grade 2 post SBRT 68,73, one 
presented at 2.5 years after treatment73. In addition two case reports described radiation 
induced adrenal insufficiency, one after SBRT of bilateral adrenal lesions153  and the other 
one developing adrenal insufficiency after radiotherapy of the spine154. Notably, another case 
report described preserved adrenal function after 40Gy in 5 fractions to the adrenal gland 
despite the absence of a contralateral adrenal gland155 that would suggest a high radio-
resistance of the organ.
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2 MATERIAL AND METHODS 
2.1 OVERVIEW OF THE STUDIES  
Table V Overview of the studies – methodology  
 
Study I: 
Reirradiation 
Study II: 
Long-term FU 
Study III: 
Adrenal 
metastases 
Study IV: 
Plexus toxicity 
Study character    
Type of study Retrospective Prospective Retrospective Retrospective 
Treatment time 
period 
1994-2004 2003-2005 1999-2013 2008-2013 
Inclusion 
criteria 
Reirradiation with 
SBRT of a 
previously SBRT-
treated lung 
target. 
PTV:s 
overlapping of 
>50% 
Peripherally 
located NSCLC 
stage I in a 
medically inop. 
patient OR 
refusing surgery 
 
SBRT-treatment 
of an adrenal 
metastasis 
SBRT-treatment 
of a lung target 
located  
superiorly to the 
aortic arch 
 
Exclusion 
criteria 
Lack of follow-up Central location Lack of follow-up 
Lack of SBRT-
data 
Lack of follow-up 
Outcome and evaluations    
Outcome 1. Toxicity 
2. Local control 
1. Local control 
2. Toxicity 
3. Survival 
1. Toxicity 
2. Local control 
1. RIBP 
2. Toxicity 
Tumor response From records WHO RECIST v1.1 N.A 
Toxicity scoring CTCAE v3.0 CTCAE v4.0 
RTOG (fibrosis) 
CTCAE v4.0 CTCAE v4.0 
Treatment characteristics    
SBRT: n(dxf) 
n=no of pts 
d= dose/fract. 
F=no of fract. 
1      (20Gyx1) 
8      (15Gyx3) 
23    (15Gyx2) 
1      (11Gyx3) 
12    (10Gyx4) 
5      (10Gyx2-3) 
16    (8Gyx4-5) 
1      (7Gyx3) 
1      (6Gyx7) 
 
57 (15Gyx3) 13(10Gyx3), 
8(15Gyx3), 
6(10Gyx4), 
4(8Gyx4), 3(8Gyx5), 
3(7Gyx8), 
2(12Gyx4), 
2(9Gyx5), 2(8Gyx3), 
2(7Gyx6), 2(5Gyx5), 
10Gyx5, 9Gyx3, 
7Gyx3, 7Gyx2, 
6.5Gyx8, 6Gyx10, 
6Gyx8, 3(5Gyx12), 
2(7.5Gyx8), 3Gyx15 
1    (17Gyx3) 
49  (15Gyx3) 
1    (12Gyx4) 
2    (10Gyx5) 
1    (6Gyx10) 
6     (7Gyx8) 
1    (6.4Gyx8) 
Target Lung Lung Adrenal Lung 
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2.2 THE RETROSPECTIVE ANALYSES 
In the retrospective analyses the patients were identified from the local SBRT-list at 
Karolinska (study I and III) and/or the dose planning systems (study III and IV). Patients 
were excluded due to lack of follow-up (study I, III and IV) or if radiotherapy data was 
missing (study III).   
 
Study no I and IV focus on toxicity after SBRT of lung targets. In study I, aiming to evaluate 
toxicity of reirradiation, all the patients reirradiated (defined as >50% overlap of the PTVs) 
for a lung target with SBRT after prior SBRT at Karolinska between 1994 and 2004 were 
included. Patients were excluded due to a lack of follow-up data. The requirement of the 
arbitrary definition of a 50%-overlap was based on a minimal volume of reirradiated lung. 
Mean lung dose (MLD) was chosen and recorded as dosimetric parameter based on the 
hypothesis that the lung would be the major OAR at reirradiation. Clinical toxicity was based 
on the patient records. Pre-specified side effects were pneumonitis, atelectasis, cough, 
dyspnea, obstruction/stenosis of airway, esophagitis, bleeding, pleura effusion, pulmonary 
fibrosis, fracture, dermatitis, hyperpigmentation, induration of the subcutis, pain and liver 
dysfunction. Local control was evaluated from the previously performed radiologic 
evaluations and largely based on the radiological statements. The Study IV aims were to 
evaluate RIBP post SBRT. The patients for this analysis were identified from the dose 
planning system and included in the analysis if they had received SBRT to a superiorly 
located lung target defined by the epicenter of the tumor being localized above the aortic 
arch. Delineation of the plexus was done retrospectively by a dedicated radiologist on the 
already performed non-contrast enhanced CT-scans with additional help from diagnostic 
imaging when needed. Toxicity was scored from the medical charts, using a modified version 
of the CTCAE v4.0 where pain and sensory/motor alterations in the area innervated by the 
brachial plexus at risk, all were considered signs of RIBP. Doses to the plexus (maximum 
dose, dose to 0.1cc, dose to 1cc and dose to 3 cc of the plexus at risk) were drawn from the 
dose volume histograms (DVH:s) and recalculated using both the linear quadratic model 
(LQ-model) and the Universal Survival Curve model (USC-model) and correlated to clinical 
symptoms of RIBP. A normal tissue complication modeling (NTCP-modeling) was fitted to 
the data using the maximum likelihood method. To establish a recommendable dose-
constraint to the plexus, a cut-off dose foreseeing approximately a <10% risk ≥ grade 2 RIBP 
was appointed. The performance of the NTCP-modeling for each of the different dose 
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volumetric variables was tested by area under the receiver operating characteristic curve 
(AUC).  
 
In study III, including patients from a wider spectrum of time (1999-2013) and from three 
different centers (Karolinska University Hospital, Stockholm; VU Medical Center, 
Amsterdam; and Rigshospitalet, Köpenhamn), the patients were identified from the local 
SBRT-registers or from the dose planning systems. The aim of this study was to evaluate 
SBRT in the treatment of adrenal gland metastases, focusing on local control and side effects. 
Patients treated with SBRT-technique for adrenal metastases were included. No minimum 
prescribed dose was required. The targets were evaluated according to RECIST v1.1 and in 
the majority of tumors (n=47), the local control was evaluated by a radiologist especially 
designated for this study. Except for a wide variety of fractionation schedules used, the 
treatment technique differed somewhat between the centers and over time, pointing out the 
use of homogenous dosage (n=3), the VMAT-treatments (n= 15) and the use of ITV (n=7). 
However, for all but two tumors, the CTV comprised the entire adrenal gland and a PTV-
margin of 5-10 mm was added. Data on toxicity was collected from the patient records and 
scored according to CTCAE v4.0, pre-specified toxic symptoms were kidney injury, adrenal 
insufficiency, abdominal pain and diarrhea.  
 
2.3 THE PROSPECTIVE STUDY 
The basis for study II was a prospectively collected patient cohort, enrolled in a phase II trial 
with the primary aim to evaluate progression free survival at 36 months for medically 
inoperable stage I NSCLC treated with SBRT. The trial was conducted within the framework 
of the Nordic SBRT-study group in Denmark, Norway and Sweden, and included patients 
between 2003 and 2005. All the patients had peripherally located NSCLC, and were deemed 
medically inoperable or refused surgery. All the patients were treated with 15Gy x 3. Follow-
up was regulated within the protocol within the first 36 months and after that, they were 
followed in accordance with clinical routines. For the long-term evaluation, clinical data was 
collected from the charts and radiological follow-up was assessed. Pre-specified radiological 
side effects included atelectasis, pneumonitis, fibrosis and pleural effusion. The main aims 
with the long-term follow-up were to evaluate late local relapses, late toxic effects and 
survival. Late presenting effects were defined as occurring >36 months.  
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2.4 ANALYSES OF THE MATERIAL IN THE STUDIES 
2.4.1 Statistical methods in the studies 
The studies in this thesis contain limited patient material (29-58 patients) having few events 
that do unfortunately limit the interpretation possibilities and the possibilities of statistical 
testing. In consultation with the statistician affiliated to this research team, statistical testing 
of the studies has been limited in order not to over-interpret clinical results. Generally, non-
parametric tests were used for the descriptive statistics to compensate for smaller number of 
patient cohorts where a normal distribution could not be expected, and for potential outliers. 
For survival analysis (or time to event analysis), we used the Kaplan-Meier method, a non-
parametric test based on the life-table technique, and often presented graphically where the 
curve changes when a subject fails but is stable when a subject is censored. The advantage of 
this method is the use of the exact time of an event for each individual in a sample and the 
use of time contributed from censored individuals. This method, however, was an estimation 
of survival function and to evaluate the uncertainty in the graph (or rate at a certain time) a 
95% confidence interval could be created. This interval is based upon the standard error of 
the survival function, which is defined by the number of individuals at risk for the event at a 
certain time divided by the individuals at risk at time 0 156. A small patient material will 
generate a wider 95% confidence interval, indicating uncertainty in the analysis. In study IV 
we also performed a receiver operating characteristic curve analysis (ROC-analysis) to test 
the prognostic value of dose to the plexus in relation to outcome and the AUC was calculated.   
2.4.2 NTCP-modeling in study IV 
In study IV, a NTCP-model was fitted to the data for each of the dose-volume parameters 
(maximum dose, dose to 0.1cc, 1 cc and 3cc) to the brachial plexus. The modeling was done 
both for the linear quadratic model (LQ-model) using BED (α/β =3) and the single fraction 
equivalent dose (SFED). SFED was calculated using the USC-model (α/β=3 Gy, α=0.206 
Gy-1, n=10 and D0=1.0 Gy and dT=5.8 Gy)157.  
A cumulative normal function was used:  
𝑁𝑇𝐶𝑃 = 1
√2𝜋
∫ 𝑒−𝑥
2 2⁄ 𝑑𝑥
𝑡
−∞
, where  𝑡 = 𝜑−𝜑50
𝑚∙𝜑50
. 
φ50 is the dose predicting a 50% probability of normal tissue complication (in this case grade 
2-3 RIBP) and m relates to the slope of the curve (fig 8).  
The probability of developing the side effect (RIBP in this case) could be estimated. The 
NTCP-model was based on data withdrawn from the DVH:s, that showed doses to different 
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volumes of the respective risk organs. However, DVH:s did not account for the anatomical 
distribution of dose within the organ which might have been crucial for the development of 
any side effects.  
2.5 EXAMPLES OF TUMOR LOCATIONS AND RISK ORGANS IN THIS THESIS 
 
 
 
 
   
Study II – Long term follow-up 
• Chestwall 
• Ribs 
• Lung 
• Heart 
• Medulla 
 
Study I – Reirradiation 
• Chestwall 
• Ribs 
• Lung 
• Heart 
• Medulla 
• Bronchi 
• Esophagus 
 
Study III – Adrenal metastases 
• Stomach 
• Duodenum 
• Intestine 
• Kidney 
• Adrenal 
 
Study IV – Radiation induced 
plexus toxicity 
• Brachial plexus 
• Trachea 
• Medulla 
• Esophagus 
 
Figure 5: examples of tumor 
locations in study I-IV. By 
permission. 
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3 RESULTS AND DISCUSSION 
3.1 OVERVIEW OF THE STUDIES 
Table VI Overview of the studies – results 
 
Study 
 
Study I: 
Reirradiation 
Study II: 
Long-term FU 
Study III: 
Adrenal 
metastases 
Study IV: 
Plexus toxicity 
Cohort      
Included pts 
No of tumors n 
29 
32 
57 
57 
58 
60 
57 
61 
Excluded pts n 5 3 12 0 
Male/female % 62/38 46/54 53/47 46/54 
Median age at 
treatment yrs 65 75 64 73 
Primary 
NSCLC* % 
13% 100% - 59% 
Metastases 87% - 100% 41% 
Median  
follow-up time m 12 41.5 12.6 24.6 
Tumor control     
Local control % 52% (5 m) 79% (5 yrs) 87% (2 yrs) - 
Regional control % - 82% (5 yrs) - - 
Distant control % - 57% (5 yrs) - - 
Toxicity       
Most common 
toxicity 
type 
G1-2 
G1-2 
G1-2 
Cough 
Atelectasis  
Pulmonary 
fibrosis 
G2-3 
G2 
Dyspnea 
Rib 
fracture 
G1-2 
G1-2 
G1-2 
Abd pain 
Fatigue  
Nausea 
G1-2 
G1-2 
Pneumonitis 
Pain thorax 
Grade 3 
type 
cough, dyspnea, 
pneumonitis, 
stenosis of airway, 
pain, pleural 
effusion, dermatitis 
VT, rib fracture, 
dyspnea 
abdominal pain, 
duodenal stenosis, 
fatigue, nausea, 
vomiting, loss of 
appetite, weight 
loss, pancreatitis 
RIBP, musculo 
skeletal, pain, 
dyspnea, COPD-
exacerb, heart 
failure, fever/chills. 
Grade 4 
type 
V cava sup 
stenosis, fistula of 
trachea and gastric 
tube 
- 
Duodenal ulcer, 
gastrointestinal 
bleeding 
Dyspnea 
Grade 5 type Bleeding (3 pts) - - - 
Study II, late effects are presented. Study III, 60 tumors were evaluable for LC. *Curative treatment. 
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3.2 TOXICITY 
3.2.1 Pulmonary toxicity 
3.2.1.1 General pulmonary toxicity in study I, II and IV 
Pulmonary toxicity was addressed in study I, II and IV through which all had different 
endpoints and inclusion of different patient categories (table VI). Without focusing on the 
special issues addressed in the different studies, the most commonly noted toxicities were in 
study I cough, atelectasis and pulmonary fibrosis, in study II dyspnea and rib fracture and in 
study IV pneumonitis and pain in thorax. Grade 3-5 toxicity was more pronounced in study I 
when compared to study II and IV, which was also expected with at least one reirradiation of 
a previously treated target and 34% of the tumors having a central location. The different 
toxicity profiles may have had several reasons within the categories of patient- tumor- and 
treatment characteristics. A few things worth mentioning are follow-up time, tumor location 
(apical/central/peripheral), size of target and number of received treatments as well as patient 
related factors, not scored in all analyses and therefore not possible to correct for. Serious 
toxicity tended to develop within the first year post SBRT6 with no increase in late toxicity 
after >36 months being noted in study II. However, the very limited follow-up time in study I 
and IV – at 12 and 24 months respectively – have led to uncertainties about whether potential 
side effects would have developed if the follow-up period had been longer. In addition, 
centrally (34% of the tumors in study I) and apically situated tumors (100% in study IV) were 
located closer to radiation sensitive risk organs, with patients vulnerable to side effects. 
Lastly, SBRT was delivered at least twice to the same part of the lung in study I, whereas 
multiple treatments were less frequent in study II and IV.  
At Karolinska with SBRT, there were no dose constraints to the lung which differs in 
comparison to the recommendations in the RTOG-study protocols and to other centers116,158. 
In study I, II and IV, 11-14% of the patients developed grade 2 pneumonitis, comparable to 
other reports, and in study II no dose-volume risk factor for pneumonitis could be established. 
In fact V20Gy and V17Gy were even somewhat lower for patients with pneumonitis grade 2 as 
compared to the non-affected patients. Of interest to note here were the findings of increased 
risk of pneumonitis from low absorbed doses to large volumes of the lungs89, frequently seen 
in VMAT treatments as compared to static field-technique, as well as the influence of dose to 
the heart in relation to the development of radiation pneumonitis (in CFRT)159. Such findings 
reflected on the complexity of assessing dose to risk organs in relation to the treatment 
technique and the clinical development of a given side effect and provide room for further 
elucidation. In conclusion, the basis for dose constraints to the lung in SBRT-treatment is 
currently scarce.  
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Figure 6: Dose distribution for a 3-fraction-treatment where red indicates the highest dose (67Gy), 
located in the tumor, and the rapid dose fall-off is then described visually by the changing colors from 
red-yellow-green-blue. Dose distribution for total doses A) >10Gy. B) >20y. C)>30Gy. D) >45Gy. 
Addressing toxicity retrospectively, especially in patient cohorts affected by metastasized 
cancer and/or pulmonary disorders, are afflicted with some uncertainty. Toxic effects such as 
pneumonitis and fibrosis in the high dose region as well as rib fractures in close proximity to 
the irradiated target are most certainly treatment related whereas other symptoms may be 
questioned with the relationship to therapy. From this context, the retrospective methodology 
has a notable limitation since the recording of a side effect is dependent on information flow 
in several lines (patient – doctor – documentation – interpretation by researcher). However, 
the greatest uncertainty prevails between grades 1-2 which often are lumped together and 
regarded as clinically acceptable. Side effects of grade 3 and above are more likely to be 
stated in the chart making an underreporting less likely. The CTCAE-scale offers an objective 
measurement to magnify symptoms limiting the possibility of widespread grading being 
inaccurate. Therefore, the toxic symptoms, especially grade 3-4 in these studies were 
considered valid.  
Except for dose to the lung as risk factor for radiation induced lung toxicity, there were also 
clinical risk factors, of which we know very little today. On note, in SBRT severe COPD 
reduces the risk of pneumonitis 92 and even patients requiring oxygen at home can be safely 
treated 160, whereas interstitial lung disease increases the risk 93. One patient in study II was 
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inoperable due to pulmonary fibrosis and he did not develop pneumonitis, but was diagnosed 
with treatment induced fibrosis grade 3 at 28 months post SBRT.  
 In regard to risk factors for dyspnea after CFRT, current data today suggested that the impact 
of performance status, FEV1, smoking history and age are equally or even more important 
than absorbed doses to the lung from within the therapeutic dose range 107, and this model is 
currently being validated by a dataset of SBRT-treated patients. This becomes an interesting 
turn in predicting toxicity since the traditionally used NTCP-models have not taken into 
consideration individual clinical patient characteristics. 
3.2.1.2 Toxicity of re-irradiation with SBRT after prior SBRT of lung tumors – Study I  
The primary aim in study I was to evaluate toxicity after reirradiation with SBRT after prior 
SBRT for a lung target. Thirty-two tumors were reirradiated one time, two tumors two times 
and one tumor was reirradiated three times. This analysis included patients with both 
centrally (n=11) and peripherally (n=21) located lung tumors as defined by Timmerman4. 
Apart from the reirradiation treatment 21 patients (72%) also received additional courses of 
SBRT for other lung metastases, which might influence the development of toxicity. Our 
analysis has shown a high rate of serious toxicity with 14 recorded grade 3-4 toxic events in 8 
patients and 3 toxic deaths in the form of bleeding. Noted risk factors for serious toxicity 
were central location, large CTV and shorter ∆T. Current data on local control and side 
effects of reirradiation with SBRT of a previously treated SBRT lung target remain quite 
limited and, apart from our analysis based on reports on 3-10 patients from small 
retrospective patient cohorts 161,162 or sub-analyses from larger cohorts with different types of 
radiation in the first and the reirradiation setting163-166. In the series from Hearn et al161, 10 
patients treated with SBRT of ≥100Gy (BED10) in 1-5 fractions, were retreated after a median 
of 14.8months (9.9-26.3) with an additional course of SBRT of ≥100Gy (BED10) in 3-5 
fractions. In contrast to our findings, they had not recorded any grade 3-5 toxicity, possibly 
explained by the fact that no tumors were located within the zone of the proximal bronchial 
tree. Interestingly though, in spite of these high doses to the tumors, 4 tumors still relapsed 
after a median of 9.9 months. 
The analysis of re-irradiation of this thesis comprises the largest patient cohort thus far 
analyzing retreatment with SBRT after prior SBRT. Grade 3-5 toxicities occurred in 11 
patients (38%), which were higher as compared to other analyses of reirradiation with SBRT 
both after CFRT and SBRT161,164-166. A few analyses reported increased frequency of grade 3 
toxicities162,167-169 and/or grade 5 events163,169,170 yet the heterogeneity within the cohorts and 
the small patient sample limited the possibilities to draw generalizable conclusions. 
Comparing the results from other analyses with those from our study remains difficult since 
some analyses included both CFRT and SBRT treatments 163-166 and some analyses also 
included both re-irradiated in-field and out-of-field recurrences162,167,168,170. Of interest here 
was the finding that toxicity was less pronounced for the subgroup of patients within the 
cohorts treated for in-field-failure when compared to those treated with an out-of-field 
failure162,167. This is a significant finding since 72% of the patients in study I had received 
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additional SBRT-courses for other thoracic targets, which may have impacted the 
development of side effects.  Noted risk factors for serious toxicity in study I were large 
CTV, central localization and short ∆T. Central location and large tumor volumes are known 
risk factors both for SBRT upfront4 and in the reirradiation setting168,169. Our findings of 
increased risk for serious toxicity with shorter ∆T could be possibly explained by the 
decreased time for repair between the treatments.  
Another question to focus on then is which dose-volume parameter was the best predictor for 
toxicity at reirradiation with SBRT. As mentioned before, there were a variety of different 
dose-volume parameters associated with pulmonary toxicity, MLD and V20 being the most 
frequently addressed. This study used MLD by summing up the MLDs from the first 
irradiation, the re-irradiation and if applicable, any other SBRT-treatments delivered at any 
point of time before the reirradiation. The background was the anticipated toxicity in form of 
radiation pneumonitis, which has been correlated to MLD84,87,89. We were not able to confirm 
a statistical correlation between lung toxicity grade 3-5 and MLD, yet in light of the diverse 
nature of the recorded serious toxicity in our analysis, this was nevertheless not to be 
expected. However, an interesting finding from another analysis found that dose to the heart 
was statistically correlated to clinical pneumonitis in a patient cohort with reirradiated 
centrally located tumors169. This was reflective of the complexity of toxicity and the clinical 
as well as dosimetric risk factors.  
Apart from the limitations due to the retrospective nature of the study, as described in section 
3.2.1.1, there are further points to be considered when interpreting the results. First 
reconstructing doses in a reliable way to different OAR was not possible, but would have 
been preferred, especially when considering grade 4-5 toxic events. Secondly, the 
heterogeneity in the patient cohort with different fractionation schedules, a wide range of 
different BED and a wide range of tumor sizes has limited the statistics and possibility to 
draw general conclusions from this collected material. Thirdly, the limited follow-up of the 
patients may have hidden late presenting effects. Fourthly, patient related factors that could 
have influenced toxicity (PS, other comorbidities, the extent of metastatic disease) were not 
recorded. Considering these limitations, one may question if the results from our analysis are 
applicable for patients who received re-treatment with SBRT in general. This study’s major 
finding that emanates here was the feasibility of reirradiation for peripherally located tumors; 
whereas centrally located tumors have had a higher frequency of serious toxicity and re-
irradiation of these should only be performed after careful consideration of the possible toxic 
effects. 
3.2.1.3 Toxicity presenting after more than 3 years post treatment – Study II 
The main aim with study II was to evaluate long-term effects of SBRT, defined as presenting 
>36 months. At three years, 34 patients were at risk for toxicity and 3 of them developed 
grade 3 symptoms possibly related to SBRT. The symptoms consisted of rib fracture at 36.8 
months, ventricle tachycardia at 38.9 months and dyspnea at 59 months post treatment. The 
patient developing rib fracture, received a maximum dose to the rib of 56 Gy (BED3,max 
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404Gy). The other patients with grade 3 late effects both received additional SBRT-
treatments; the former with a significant history of heart disorders including arrhythmia and 
0.3cc of the heart exceeding our local maximum dose guideline to the heart during the second 
treatment. Late presenting rib fractures excepted, reported late grade 2 side effects ranged 
between 3-9% in frequency (COPD-exacerbations, cough, dyspnea, exudates, lung infection, 
upper airway infection), which ought to have been an acceptable level considering a high 
likelihood to be cured. 
At the time of treatment of these patients (2003-2005) there were no dose-constraints for the 
rib cage or the chest wall, 7% and 4% of the patients experienced ≥ grade 2 chest-wall pain 
and rib fractures respectively within 3 years, comparable to the other reports. However, rib 
fractures ≥ grade 2 presenting after 3 years occurred in 18% of the patients at risk, and may 
have been avoided with today’s dose restrictions to the chest wall. Pulmonary function 
changes are of major interest, yet unfortunately only a few patients had made PFT:s after 2 
years (13 patients at 24 months and 8 patients at 36 months), making data scarce for 
evaluating the cohort on long-term effects. It is also noteworthy, that in addition to this study 
treatment, six patients (all surviving >36 months) received additional SBRT treatments to the 
lung that could have been an influence on their development of side effects.  
Reports on long-term toxicity post SBRT were scarce and complicated with symptoms from 
other intercurrent diseases. As concluded from our collected material, the most important 
message here showing that there was no increase in late-presenting toxicity. This is in line 
with the recently presented material from long term follow up of the RTOG 0236 trial34. 
 
3.2.2 Abdominal toxicity 
3.2.2.1 General abdominal toxicity in study III 
Study III addresses abdominal toxicity, the most commonly noted being grade 1-2 abdominal 
pain, grade 1-2 fatigue and grade 1-2 nausea, which was comparable to other reports on 
toxicity post SBRT of abdominal targets145,146. Grade 3 toxicity was recorded eight times in 
seven patients and grade 4 two times in one patient (duodenal ulcer and GI-bleeding), i. e 
12% of the patient cohort suffered grade 3-4 side effects. Grade 3-4 toxicity presented either 
very early ≤3.1 months (5 patients) or very late, >3.5 years (2 patients) post treatment. 
However, both patients with late-presenting toxicity and the one patient experiencing grade 4 
toxicity also received additional radiotherapy towards abdominal targets which may have 
influenced the toxic effects. The dose contributions from these additional radiotherapy 
regimens have been reported separately, with no intention of creating summations of doses to 
the organs at risk. The reason behind constitutes the uncertainty in assessing normal tissue 
repair (other radiotherapy treatments for patients with ≥grade 3 intestinal toxic effects were 
given between 7.5-30 months from the study treatment) and the uncertainty in evaluating 
which parts of the OAR were being affected with significant dosages.  
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Eight patients experienced pain or symptoms of pressure from their adrenal metastasis prior 
to treatment, and four of them responded to treatment, two did not respond to treatment and 
two were not evaluable for assessment of symptom response.  
 
3.2.2.2 Toxicity in the gastrointestinal tract 
Toxicity of SBRT of adrenal metastases has generally been mild and our frequency of ≥grade 
3 toxicity was higher when compared to other analyses; 12% vs 0%67-75, with the exception of 
one report where grade 3 toxicity, was scored 6 times in a patient cohort comprising 26 
patients, however, five of the toxic effects being hematological76. In comparison to 
gastrointestinal toxicity of other abdominal targets post SBRT, the most commonly reported 
grade 2 symptoms consisted of abdominal pain, nausea and vomiting and correspondingly for 
grade 3 effects gastrointestinal perforations, nausea and diarrhea145,146. The types of reported 
symptoms were similar to ours. Plausible explanations to our increased frequency of serious 
toxicity were doses to OAR and patient related factors.  In addition, four of the patients in 
study III suffered from symptoms of a general character that may be hard to attribute to a 
specific organ system. 
To assess doses to the GI-OAR, we evaluated dose to the stomach and the small bowel for 
those patients clinically regarded as being at risk for toxicity (defined as the metastasis being 
localized ≤ 1cm to a GI-OAR). In summary, 14 patients without grade 3-4 side effects had 
tumors in close proximity to the stomach, 13 to the duodenum and 16 to the small bowel. 
Only one patient had a target located close to the colon. All patients with grade 3-4 side 
effects had at least one GI-OAR located ≤ 1 cm of the treated adrenal metastasis. This study 
evaluated Dmax and D5cc based on our local guidelines and the QUANTEC-report from 
2010149. Our local guide lines recommend D5cc ≤ 23.7Gy (3 fractions, stomach and intestines) 
and the QUANTEC-report recommends for the stomach Dmax ≤ 22.5Gy to approximately 5cc 
or 4% and Dmax<30Gy (3 fractions); and to the small bowel Dmax < 30Gy (3-5 fractions)149. 
Four patients of the twenty-seven who exceeded the QUANTEC-recommendations in study 
III, developed grade 3 toxicity (weight loss, abdominal pain, loss of appetite, nausea,  
duodenal stenosis). Both patients with late-presenting serious side effects (abdominal pain 
and duodenal stenosis) received doses far overruling the expected tolerance level of the 
respective OAR, whereas only 2 of the patients with early presenting grade 3-4 toxicity 
received high doses to the OAR. This lack of dose response has posed questions on the 
accuracy of the side effect grading and its relation to SBRT, the possibility of faulty dose-
constraints and the possible effect of other contributing factors such as miss of target and the 
unintended administration of potential radiosensitizers. The impact on side effects from the 
low-dose region, affecting larger parts of the intestines or stomach has not been addressed in 
this analysis and there is a need for further elucidation.  
Patients included in study III all had metastatic disease and 55% and 59% received systemic 
therapy before and after SBRT-adrenal respectively. No patient purposely received 
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chemotherapy concurrently with the study treatment. However, a duodenal ulcer diagnosed 
with gastroduodenoscopy approximately one month post SBRT and complicated with 
bleeding grade 4, evolved in a patient receiving low doses to the duodenum. This patient also 
suffered from diabetes, medicated with cortisone and immunosuppressants due to a liver 
transplantation and received chemotherapy at the time of the side effect, possibly making him 
more vulnerable to toxic symptoms. There was also an uncertainty in the chart as to whether 
the patient temporarily stopped with chemotherapy at the time of SBRT. This is of course a 
complicating matter since such systemic agents may add to the risk of toxicity; either causing 
GI-toxicity themselves or function as radiosensitizers for both tumor and normal tissue. 
Gemcitabine is a chemotherapeutic agent and known radiosensitizer, frequently used in the 
treatment of pancreatic cancer. Treating pancreatic cancer with the sequential combination of 
single fraction (25Gy) SBRT and 1-9 cycles of gemcitabine resulted in the development of 
late toxicity (def. as ≥ 3 months) with GI-ulcers in as much as 44% of the patients171. In 
contrast, two other analyses of 1-3 fractions of SBRT and sequential gemcitabine for 
pancreatic cancer, found a lower frequency of late GI-toxicity with grade 2-4 events 
occurring in 15% 172 and 6% 173 of the patients respectively. It is worth pointing out that all 
three analyses had strict dose constraints to the duodenum, however not published in the first 
report why comparison of doses is impossible. A case report from Japan also highlights the 
possible elevated risk for toxicity with the combination of SBRT and chemotherapy174. In 
addition to traditional chemotherapy there are anticancer agents with different mechanisms of 
action which may affect the outcome of radiotherapy. The administration of bevacizumab or 
Sorafenib, both VEGF-inhibitors, prior and/or post SBRT for abdominal lesions, resulted in 
35% of the patients with VEGFi, developing grade 3-5 bowel toxicity, why the authors 
concluded that other therapies than SBRT may be used if treatment with VEGFi in the near 
future is likely175.  
Another characteristic worth taking into consideration is that the stomach and the intestines 
are highly mobile structures also affected in shapes and volumes by their contents at the time 
of treatment. Currently, when treating adrenal metastases fiducial markers were used, placed 
in the vicinity of the target, for image guidance and the patients were treated on an empty 
stomach. Historically, this has not always been the case, leaving room for set-up errors and 
inter-fraction movements. On the other hand, treating tumors in the SBF has resulted in high 
grade of local control in clinical evaluations of the method6,42. Another aspect is the 
movement of the target itself. When treating adrenal metastases, Katoh et al71 looked at the 
movement of a fiducial marker placed in the vicinity of the adrenal and concluded that it 
moved <1cm in the supine position, though the treatment technique was different to ours.  
Interpreting toxic effects in a heavily metastasized patient cohort is delicate. Toxic symptoms 
may be both under- and over reported (as described in section 3.2.1.1) due to general cancer 
morbidity symptoms. The majority of the reported serious toxicity was such general 
symptoms (fatigue, nausea, weight loss, loss of appetite and vomiting), which may have been 
caused by the cancer itself or by other antitumor agents. The heterogeneity between the 
presented symptoms limited the statistical testing of any differences.   
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3.2.2.3 Kidney toxicity 
We experienced two complicating situations when addressing kidney toxicity; the first being 
that eight patients only had one functional kidney due to nephrectomy, and the other one 
being four patients who received bilateral treatments for adrenal metastases. Doses to the 
kidney would preferably be described as a dose to the ipsilateral and contralateral kidney 
respectively, yet due to the above-mentioned situations, we instead considered the kidneys as 
one OAR and evaluated doses to total kidney volume for each patient. During follow-up, we 
could not confirm any kidney toxicity or increase in S-creatinine of >50% as compared to the 
baseline value at three (n=35) and six months (n=33) post SBRT respectively. This was 
neither to have been expected since VBED3,40Gy (the currently used dose-volume parameter) to 
the total kidney volume was limited. Our finding is in line with the findings from Svedman et 
al176 who investigated seven patients, treated with SBRT to a single functioning kidney. None 
of these patients experienced kidney toxicity and V15Gy was kept <40% for three or four 
fractions in all patients.  
3.2.2.4 Adrenal insufficiency  
Study III addresses adrenal insufficiency, which was noted in five patients (4 with grade 2 
and 1 with grade 1) after a median of 4.1 months (0-94.2). Interpreting adrenal insufficiency 
in a retrospective cohort with patients with spread cancer was complicated due to the similar 
nature of both general cancer morbidity symptoms such as fatigue, low blood pressure and 
electrolyte disturbances, and symptoms of adrenal failure. Therefore, the grading of adrenal 
insufficiency in study no III, was based on the diagnosis made by the treating physician. No 
routine assessment of adrenal insufficiency was performed in the clinic and for the three 
patients who performed an ACTH-stimulation test, their test scores fell out of the normal.  
Another concerning issue was that cases with adrenal insufficiency may have remained 
undiagnosed, since 19 patients had cortisone treatment due to another indication (brain 
metastases, generally invigorating or other).  The most important future aspect is to foresee 
which patients are at risk for SBRT-induced adrenal insufficiency. Theoretically, based on 
the principle that clinical symptoms appear when >90% of the cortices of the adrenal 
glands66,150 are lost, one might imagine that three categories of patients would be at greatest 
risk of this side effect; 1) patients receiving SBRT bilaterally, 2) patients with only one 
functioning adrenal gland receiving SBRT towards that, 3) patients with metastatic disease in 
both adrenals and receiving unilateral SBRT. We looked at those categories in study no III 
(table VII). Fourteen patients belonged to either of these groups and 3 of them developed 
grade 2 adrenal insufficiency (i.e requiring substitution therapy). For the remaining eleven 
patients in these risk groups, four had cortisone treatment which may have hidden the side 
effect, but otherwise we could not confirm any particular reason for why adrenal 
insufficiency did not develop (7 patients received >94Gy (BED10) to 98% of the CTV, 
median FU was 12.9 months (2.6-75.1), tumor location was right sided (n=5), left sided (n=4) 
and bilateral (n=2).  
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Finally, forty-four patients received radiotherapy to treat one adrenal metastasis with the 
other adrenal gland being intact and two of them had still developed adrenal insufficiency. In 
surgical material 22% of the operated patients developed symptomatic adrenal insufficiency 
post adrenalectomy; obesitas, hypertension, diabetes and large tumor size had been risk 
factors177.  Further addressing this issue in a prospective trial, assessing adrenal functioning 
biochemically and clinically regularly post SBRT, is a necessary next step. 
 
Table VII Irradiation towards adrenal tissue 
 No of patients Adrenal insufficiency 
SBRT of all adrenal tissue   
Bilateral metastases – 
SBRT of both 
4 G2: 2 
Bilateral metastases – 
SBRT of one  
8 G2: 1 
Unilateral metastasis 
– single adrenal gland 
2 - 
SBRT with functioning adrenal tissue remaining 
Unilateral metastasis 
– two adrenal glands 
44 
G1: 1 
G2: 1 
G1: grade 1. G2: grade 2. 
3.2.3 Radiation induced brachial plexopathy 
Radiation induced brachial plexopathy (RIBP) was assessed in study IV, where it was noted 
in seven patients; grade 3 in four patients and grade 2 in three patients with the first 
symptom presenting after a median of 5.8 months (0.7-12.9) and the worst grade after 8.7 
months (6.1-30.6). None of these patients received neurotoxic chemotherapy, had local 
failure or diabetes as potential contributors to the development of their side effects. The 
three worst affected patients (fig 7), diagnosed with neurophysiological examinations, had 
severely handicapping symptoms with pain, sensory and motor alteration. Those patients 
with pain were clinically diagnosed and one of them had symptoms showing improvement 
over time and one patient only suffered pain on one occasion. However, apart from the 
study treatment, three patients in the cohort also received significant doses to the brachial 
plexus from additional radiotherapy treatments, one of them had developed grade 3 RIBP. 
Interestingly, when reviewing the dose-plans for the patients with RIBP, the patients 
suffering from the most severe symptoms had all received high doses affecting the entire 
circumference of the plexus for several centimeters whereas 8 of the 10 patients receiving 
BED3,max >130Gy and had not developed RIBP, only received the dose along with the 
structure, not affecting the entire circumference. 
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Figure 7: Doses in color wash exceeding BED3 130Gy for the three patients suffering from serious 
RIBP (motor and/or sensory affection).  
As mentioned in the introduction, the largest analysis of SBRT-induced RIBP constituted the 
analysis from Forquer et al136 who, based on 37 treatments and seven cases with grade 2-4 
RIBP, concluded that Dmax to the brachial plexus should be < 26 Gy for a 3-4-fraction-
treatment. However, two other analysis, one on SBRT-material and one on CFRT had 
suggested higher dose restrictions of Dmax ≤35 Gy and V30Gy≤0.2cc (4 fractions)116 and Dmax 
≤78Gy and V76Gy≤1cc (CFRT)132 respectively. The latter pointed out the importance of 
achieving local control to avoid the possible effect of a local failure, causing tumor induced 
brachial plexopathy which may be even more disabling132. 
Also of note in study IV was its being compromised with limitations similar to the other 
studies i.e retrospective materials, heterogeneity within the cohort, uncertainties in addressing 
toxicity, small patient cohorts and limited number of patients presenting symptoms etc. 
However, in addition, there were also limitations specific for study IV. Firstly, there are 
treatment related uncertainties such as the impossibility to correct for absorbed doses to the 
plexus from other radiotherapy treatments and the fact that we do not use hard dose 
constraints to this structure, yet over the years an increased awareness of this OAR has been 
noted. Secondly, Dmax to the plexus refers to a very specific point and in a fine structure like 
the brachial plexus which follows the lung almost horizontally; there were uncertainties as to 
whether the location of Dmax from the dose-planning CT was representative for the location of 
Dmax during treatment.  Apart from set-up-errors and intra-fraction movement, uncertainty 
which also prevailed in the delineation of the structure as pointed out by a validation analysis 
of the RTOG-contouring atlas178. These were all issues to be born in mind when interpreting 
the created NTCP-model (fig 8) as well as the general fact that NTCP-modeling does not 
accurately describe the dose-distribution within the organ.  
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Figure 8: NTCP-modelling for BED3,max. Crosses represent patients with RIBP and rings represent 
patients not developing RIBP. The dotted line shows the level of BED3,max 130Gy, AUC 0.87. 
In study IV, the BED3,max NTCP model showed the best fit of the data (fig 8). Considering the 
prediction by the NTCP-model as well as aforementioned uncertainties, we suggest to 
increase the dose-constraint to the brachial plexus to Dmax ≤30Gy for three fractions. 
3.3 LOCAL FAILURE 
3.3.1.1 Local recurrences after reirradiation – study I  
Local control of SBRT was high, yet when considering the increasing number of patients 
being treated with this method, the absolute number of local failures will be on the increase. 
How should such local failures be treated? Technically, surgery remains one option. 
However, in spite of the favorable outcomes with long term survival, high rate of local 
control and limited toxicity reported in small patient cohorts treated with salvage surgery 
(most often lobectomy) of local failures post SBRT179-181, this alternative is seldom an option 
for patients previously deemed medically inoperable. Retreatment of a local failure of SBRT 
with CFRT with 60-70Gy in 30-35 fractions have been described with low toxicity but also a 
disappointingly low local-progression-free survival of 34% at 1 year, thus questioning the 
benefit of this treatment182. Further alternatives comprise systemic therapy, observation only 
and retreatment with another course of SBRT. SBRT has the advantage over CFRT of 
smaller treatment margins, a rapid dose fall-off minimizing the dosage to normal tissue, 
higher treatment doses and shorter overall treatment time. These advantages can be utilized in 
the retreatment setting both of local failures after SBRT and after CFRT. 
In study I – evaluating reirradiation with SBRT after prior SBRT of a lung target, eight 
patients progressed locally and six patients could not be properly evaluated. This resulted in 
52% of the patients achieving local control at 5 months. This is a remarkably low number in 
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the context of SBRT and in comparison to our own material with a 92% local control rate at 3 
years 6 and 79% at 5 years (study II) using the same technique. Here it is important to 
remember that the patients in study I were treated in the early era of SBRT when normal 
radiological changes post SBRT were not well known and bulky fibrosis could be easily 
mistaken for a relapse. At data collection for the study, the radiological pictures during 
follow-up were often unretrievable due to the long timelapses, when local control was based 
on historical radiological statements made in the everyday clinic. The tumors suffering local 
failure were metastases from NSCLC (n=4), CRC (n=3) and hepatocellular carcinoma (n=1) 
and only two of them received BED >100 Gy (prescribed dose 15Gyx3) at re-irradiation. A 
general comparison between local control after SBRT upfront versus SBRT as re-irradiation 
after prior SBRT, revealed poorer local control with 22-40%161,162,166 of the patients having 
relapsed within 9 months post re-irradiation 162,166. Possible explanations to these inferior 
results might result from the underlying tumor biology with survival of radio resistant cell 
clones after the first treatment and rearrangement of the tissue structure after the first ir-
radiation, which might cause increased hypoxia. From our analysis, it was also noted that the 
SBRT doses generally were low (only 6 of the 32 tumors had prescribed BED >100Gy at the 
re-irradiation). Yet another question was the magnitude of the actual delivered dose to the 
tumor, considering among other things the lack of image guidance at this point of time 
3.3.1.2 Late presenting local failures – study II 
In study II – focusing on late presenting relapses, we reported seven local recurrences during 
the entire follow-up time (table VIII); four occurred within 3 years and three after three years. 
At present, there is a growing body of evidence for late effects of SBRT with generally high 
5-year-local control rates after SBRT between 78%-90% 36,37,39,87,90,183, and subanalyses from 
some of the cohorts showing superior results for small tumors 37,39,87. The most recently 
presented long-term results with a median follow-up 4.0 years, comes from the RTOG 0236-
trial, reporting a 5-year-local control rate of 93% after SBRT 18Gyx3 (BED10=151.2Gy)34. In 
comparison, our 5-year-local control rate of 79% was in the lower range and finding one 
single explanation for this would be complicated since local control does rely on several 
different parameters, partly influencing one another. Risk factors for early local relapse 
included big tumor size37,87,184 and lower treatment doses39,185,186. Risk factors for late local 
relapses have not been established and may differ due to other biological mechanisms and 
interactions between the host and the tumor. First, looking at dose-volumetric data from 
reports with 5-year-local control rates at ~90%34,36,90, the majority of their patients did receive 
somewhat higher doses (BED10 105-151Gy) as compared to our cohort, while at the same 
time, the proportion of T2-tumors was higher in two studies36,90 . Increasing the dose may 
increase both local control186 and, for T2-tumors, survival 187. Second, the refinement of the 
SBRT-technique in recent years with improvement in dose calculations, geometrical 
verification and tumor movement assessment has hopefully improved treatment outcome, 
although uncertainity still remains. Taking these factors into consideration, one might still 
hypothesize that our standard dose (15Gyx3 corresponding to BED10 of 112.5Gy) might be 
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too low, especially for large tumors that have more tumor cells to kill off and also may be 
more radioresistant due to hypoxic areas. 
Another interesting aspect concerns which type of tumors that recur after several years and 
what mechanism lie behind this. Unfortunately, only a few reports describe the characteristics 
of the tumors relapsing after >3years (table VIII) however one interesting finding is that 
tumors who relapse later are T1-tumors41,42. However, drawing specific conclusions from the 
limited number of cases from these three cohorts (table VIII) is difficult; T2-tumors 
comprised 60%42 of the tumors in one study, but only ~28% in the other two41, why fewer 
patients with large tumors were at higher risk from the beginning. Another aspect is the 
negative influence on survival from large tumors, reducing the number of patients at risk at 
later times for evaluation. In study II in this thesis, such a relation could however not be 
verified. Another interesting aspect is that even after surgery, where the entire tumor lesion is 
removed, 9% of the recurrences after surgical resection of NSCLC occur after 5 years, 1% 
being local recurrences18. Thus, it is important to understand more of the biology of late 
presenting relapses, especially when applying SBRT to operable patients where long-term 
survival is expected. Biopsies before treatment and at suspicion of local failure are important 
to understand more of the underlying mechanism.  
 
Table VIII Characteristics in early and late local relapses 
Study Dose Early local relapses ≤36 m Late local relapses >36 m 
 (BED10) 
Gy 
T-stage 
 
Number 
n 
Time  
m 
T-stage Number 
n 
Time 
m  
Baumann 
200642 
60-120 T2 13 <36 T1 3 >36-49 
Matsuo 
201241 
105.6 N.S N.S N.S T1 3 101-109 
Current 
study 
112.5 T2 4 10-36 T1 3 38-76 
N.S: not stipulated 
A notable limitation with our study is the diagnostic method of the late local failures (x-
ray=1, CT=1, PET=1). No patient was invasively diagnosed which leaves room for 
questioning the accuracy of the local failures since bulky fibrosis often developed post SBRT. 
Focusing on late presenting relapses; PET-CT or the presence of ≥3 high risk CT-features 
(used in 1 patient each) are accurate diagnostic methods45 44. Hence, these two late local 
failures are most certainly true, whereas the local failure diagnosed by just x-ray is highly 
questionable and probably does represent bulky fibrosis. 
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Noted risk factors for local recurrence throughout the observation period were large tumor 
size, probably reflecting the insufficient dose in relation to tumor size, and the finding that 
57% of the local relapses were located in the lower lobes, possibly reflecting a relative under 
dosage of the target due to large breathing motions. 
3.3.1.3 Local control of adrenal lesions – study III 
Study III shows local control rates of 92% and 87% at 1 and 2 years respectively which is 
comparable to67,68,71,76 or superior69,70,72-75 to other reports. Five patients with six tumors 
experienced local failures after a median of 8.2 months; two came from rectal cancer, three 
from NSCLC and one from malignant melanoma. Risk factors for local recurrences were 
large tumor volume and lower doses. Due to differing risk situations and various local 
protocols, the patients in study III were treated with a variety of fractionation schedules 
resulting in 17% of the patients having prescription doses of BED10 <58Gy, 21% between 
58Gy-70Gy, 41% between 71-99Gy and 21% > 99Gy. There was a tendency towards poorer 
coverage of doses for cases with local failures as compared to cases with local control (fig 9).   
 
Figure 9: Doses in BED10 covering 80-98% of the CTV and PTV for cases with local control and local 
failure respectively in study III. There was a tendency for poorer coverage of doses for the cases with 
local failures as compared to the cases with local control.  
3.3.1.4 Shortcoming in assessing local control 
There are uncertainties in the assessment of local control in the studies of this thesis (study I, 
II, III). First, the lack of cytological/histological confirmation or PET-CT when local failure 
was suspected is notable limitations. For a pulmonary target suspicious of failure, 
0 
20 
40 
60 
80 
100 
120 
80% 90% 95% 98% 80% 90% 95% 98% 
B
ED
 (α
/β
 1
0G
y)
 
CTV  
Local control 
Local failure 
PTV 
  46 
transthoracic needle biopsy was in many cases not a viable diagnostic option due to reduced 
lung capacity of patients with COPD. In this situation, PET-CT had a sensitivity and 
specificity of 100% to reveal a local failure45, but was less common in the early 21st century 
when these patients were treated and followed. The occurrence of ≥3 high-risk CT- with 
features for local recurrence has a sensitivity and specificity of >90%44 and may be a feasible 
option for evaluation of local control within the studies I and II and relevant cases in study 
IV. However, if possible a local recurrence in the lung should be confirmed, preferably by 
histology/cytology and if this is not possible, by a PET-CT. In study III (adrenal metastases), 
judging local control is less complicated since bulky fibrosis does not blur the picture. A 
dedicated radiologist performed the evaluations in study II and III, which strengthens our 
diagnostic accuracy.  
Second, study I and III are also compromised with the uncertainty on the malignant potential 
of the lesion prior to SBRT that may have affected the later evaluation of local control. In 
study I, one might possibly suspect that a bulky radiation fibrosis in the early era of SBRT 
could be mistaken for a local failure, which was the indication for re-irradiation. In study III 
(adrenal metastases), 28 tumors were diagnosed as metastatic lesions by CT-examinations, 
evaluated in the everyday clinic. Although, assessed by experienced radiologists, we did not 
reevaluate the lesions for typical signs of malignancy prior to SBRT (described in 
introduction), why local control of these lesions might be questionable. Overall, some 
metastatic patients received other anti-cancer therapy, possibly affecting local control of the 
SBRT-treated lesion. These two last shortcomings are mainly due to the retrospective nature 
of the studies.  
3.4 OUT-OF-FIELD FAILURE 
Study II addresses out-of-field failures, whereas the other studies did not due to the metastatic 
state of the patients and the wide variety of histology and primary tumors. Out-of-field 
failures occurred in 15 patients (26%) as first presentation of failure, 11 of them presenting 
within 36 months. During the entire follow-up period, when the out-of-field failures are 
subdivided into regional failure and distant failure, 7 patients were diagnosed with regional 
relapse and 15 patients with distant metastases at some time during follow-up, both appearing 
after a median of 25 months (2.9-84.4) respectively.  
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Figure 10: KM-analyses (study II) of A) Regional failure and B) Distant failure. 
The impact of tumor size on tumor progression has not been fully elucidated yet. Large tumor 
volume is a risk factor for systemic progression which to some extent is supported by our 
finding of shorter time to progression according to tumor stage, which is in accordance to the 
reports of others. However, PET-CT became a standard procedure in the diagnostic work-up 
for early stage NSCLC during the inclusion period of the study, and only 18 patients (32%) in 
the cohort underwent an 18F-FDG-PET for cancer staging, leaving a possibility that 
disseminated disease already existed at diagnosis. Improving the diagnostic accuracy of 
staging is one of the great challenges in treating NSCLC. 
 In patients with suspected or proven potentially resectable NSCLC, a randomized trial 
showed that PET-CT followed by further invasive diagnostic or therapeutic procedures led to 
the upstaging of 27% of the patients as compared to 12% of the patients doing invasive 
diagnostic or therapeutic procedures43. Diagnosis of a suspected relapse is equally important, 
but invasive diagnosis may also in this situation be afflicted with technically complications, 
especially when the suspected lesion is located in the lung. 
3.5 SURVIVAL 
3.5.1 Stage I NSCLC – study II 
In study II we noted a disappointingly low overall survival rate at 4 and 5 years, of 39% and 
30% respectively, which is somewhat compensated by the cancer specific survival of 82% 
and 74% at the corresponding time points. Seven patients were alive at the time of the 
analysis fourteen patients were deceased due to lung cancer and 36 due to intercurrent 
disease. Three questions that arise are if SBRT has contributed to the limited survival of the 
patients, which risk factors can be identified for decreased overall survival and if these 
patients did receive any benefits from the treatment or not.  
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The five-year-overall survival rate post SBRT for medically inoperable NSCLC is in the 
range of 21-60% 19,38,42,95,183,187 and inferior to the rates of 66-75% reported after surgical 
resection 18,19. This is probably a reflection of death due to intercurrent diseases, an 
assumption further supported by the finding of 5-year-survival rates >80% post SBRT in 
cohorts with a large proportion of operable patients and/or small tumors33,188. It is also 
supported by the observation that OS has been similar for SBRT and surgery as concluded 
from results of analyses using matching techniques or adjusting for age and inoperability 
19,24,26,27. In comparison to CFRT of early stage NSCLC the estimated 5-year-survival from 
CFRT is historically very low, about 21%29. However, the SPACE-trial, randomizing 
medically inoperable patients in the 21st centrury between CFRT and SBRT, could not affirm 
any differences in survival between the treatments189. This result may mirror the 
improvement of radiotherapy in general, but it should also be noted that toxicity and 
convenience for the patient were in favor of SBRT in the SPACE-trial. In study II, 65% of the 
patients were inoperable due to COPD that is a life threatening illness. Patients with COPD 
all stages have an expected 5-year survival of ~45-73%190-192. The low survival rate in study 
II may therefore not entirely be explained by COPD. Plausible explanations could be the 
younger age190,191 and more females190 in the COPD-studies as well as the contributing effect 
of other diseases; for example heart-failure has a dismal prognosis with 5-year-survival of 
approximately 27193. 
Risk factors for inferior survival post SBRT include large tumor volume38,187,188, CCI ≥ 638 
and male gender187 . Another interesting aspect is the radiation dose. Keeping BED10 >100Gy 
has long been associated with improved local control and survival194. Recent analyses have 
shown a significant survival benefit if prescribing doses BED10 ≥ 150Gy for T2-tumors187, 
but the results have to be verified prospectively.  
Ninety percent of the patients in study II had COPD and/or heart disorders rendering them 
medically inoperable. There is of course a possibility that damage from radiation may worsen 
the co-morbidity itself with decreased organ function and shortened life time. However, an 
interaction between co-morbidity and SBRT with a significant negative influence on survival, 
has not been confirmed38. Neither could two studies addressing the impact of low FEV1 on 
survival, show a negative influence of poor pulmonary function pretreatment when 
comparing patients with better and worse performance110,114. Similar trends have been 
observed by other research, possibly reflecting the reason for inoperability – cardiac 
disease113. Another aspect is the age of the patients since 19 patients (33%) in study II were ≥ 
80 years old at the time of SBRT possibly affecting survival rates. Overall survival at 3 years 
for this age group and treatment indication has been reported to only 48% for medically 
inoperable cases195. This low number should not automatically exclude elderly patients from 
the treatment and it must be weighed against the 2-year-mortality rate of >70% if the cancer 
is left untreated27. In answer to the first question above, it is unlikely that SBRT has 
contributed to the short survival. The second question is more difficult, low pulmonary 
function or high age should not isolated preclude the patient from therapy, but the impact of 
the combination from multiple negative factors needs to be further looked in to.  
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3.5.2 Metastasized patients – study I and III 
The patients in study I and III, comprising metastasized patients, had median survival of 19 
and 16 months respectively, which are, but to some extent expected from patients with 
metastatic spread. The major question in this setting is the basis for delivering an aggressive 
local therapy with risk of serious toxicity to heavily metastasized patients with expected 
limited overall survival. In study III, the demographic pattern over time (fig 11) shows that 
even though increasing the number of absolute treatments, both side effects as well as local 
recurrences have decreased in frequency, justifying the current treatment patterns. 
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Figure 11: Number of patients treated during different time periods and with different prescribed 
doses in BED10. Noted local failures (LF+) and grade 3-4 side effects (AE+).  
SBRT in the metastatic setting should primarily be considered where untreated metastases 
may cause severe local cancer morbidity symptoms due to tumor progression or when a high 
gain in overall treatment effect may be expected, such as the oligometastatic situation. 
Another special situation is NSCLC with a single adrenal metastasis, in which ablative 
therapy of the metastasis may achieve favorable outcome with long-time survival70,72. A sub-
analysis from study III on patients with a single adrenal metastasis versus patients with 
multiple metastases including an adrenal lesion shows similar promising results.  
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3.6 FRACTIONATION IN SBRT 
The Linear-Quadratic model (LQ-model) describes quantitatively the effects of fractionation 
that was empirically found in the 1920s. At present, it is commonly used in CFRT in the 
clinic to convert doses from different fractionation schedules into biologically equivalent 
doses (BED) to compare the schedules with respect to tumor- and normal tissue effects. 
Although well validated for small fraction doses, the LQ-model has been questioned for high 
fraction doses as used in SBRT, due to an overestimation in cell-killing effect for large doses, 
seen from in-vitro data. BED, according to the LQ-model, is based on the values of the total 
dose (D), the fraction dose (d) and the α/β-value. The α/β-value describes the damaging 
effect of radiotherapy to the cell; the α-value stands for the cell-specific un-repairable lesions 
and the β-value represents the cell-specific combination of repairable sublethal lesions. 
Tumors generally have a high α/β-value whereas a low α/β-value is used to estimate late 
normal tissue effects. The LQ-model predicts a larger therapeutic window with reduced risk 
for toxicity when increasing the number of fractions, in correspondence to what is observed 
in the clinic. 
 More recently, many centers have more frequently been using an increasing number of 
fractions in SBRT (sometimes called risk adapted SBRT) from 3 up to about 10, when the 
tumor is located in close proximity to an OAR. The intention, by this strategy is to spare the 
normal tissue and avoid any late side effects, and is adopted to SBRT as a direct extrapolation 
from the experience in CFRT. Advocates of using the LQ-model for high fraction doses point 
out that results from pre-clinical and clinical data do not support the need to change the LQ-
model and that the excellent clinical results with SBRT rest upon the technical possibilities to 
deliver much larger biologically effective doses196,197. However, the validity of LQ at high 
doses has been questioned by critics based on both in-vitro and in-vivo experimental data and 
alternative models have been suggested; for example the Universal Survival Curve model 
(USC-model)198 and the generalized linear quadratic model (gLQ-model)199 . Interestingly, 
non-LQ models such as USC predicts a larger gain in therapeutic window compared to the 
LQ model by increasing the number of fractions, at doses commonly used in SBRT157. 
Today, however, conclusive clinical in-vivo data from SBRT, supporting a gain in therapeutic 
window by increasing the number of fractions from a few up to about ten, is still lacking. 
In addition to the debate on the role of fractionation in SBRT, there are also theories that 
completely different mechanisms, not accounted for in radiobiological models, may play an 
important role; hypoxia, especially in single-fraction SBRT may increase the 
radioresistance200, vascular damage from high doses may cause delayed, necrotic cell death 
which causes the LQ-model to underestimate the cell-killing effect201 and immunologic 
effects may activate and attract immune cells that might kill cancer cells or even damage the 
vasculature202.  
The NTCP-modeling in study IV was done both with the LQ-model and with the USC-model 
in order to see if there was any difference in predictive power between the two. The USC-
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model is a hybrid between the LQ-model (at low doses) and the Single Hit Multitarget model 
(SHMT) (at high doses), and was constructed with the motivation that the LQ-model works 
well in the low-dose region whereas the SHMT performs better in the high-dose region198. It 
was developed by Park et al and its goodness-of-fit, tested on NSCLC-cell lines, was superior 
to that generated from the LQ-model198. In the NTCP-modeling in study IV of this thesis, 
there was no major difference between the models (LQ vs USC) for predicting toxicity. There 
was no perceived benefit for increased fractionation, but the patient material was limited and 
the follow-up was short of patients who received “risk-adapted” fractionation schedules. 
Interestingly though, when treating with SBRT at our institution, the maximum allowed dose 
to the plexus has historically been decided individually for each patient at the discretion of 
the treating radiation oncologist. However, since 2011 we have increased the awareness of 
the brachial plexus as an OAR by routinely segmenting this structure in the planning CT 
images and occasionally used a “risk adapted strategy” with an eight-fraction-treatment for 
tumors in close proximity to the plexus. Over this period, no RIBP has been reported, but the 
evidence for drawing conclusions from such a finding are scarce since the follow-up was 
limited and the anatomical distribution of the high-dose-region could also play an important 
role here. 
Modeling SBRT-induced toxicity is of major importance. The predictive power of any model 
is primarily dependent on the input data in the modeling. Thus, there is a future need for data 
collection, with very well defined end-points for both the modeling and treatment data. 
Regarding the latter (in study IV), maximum doses are shown to have a higher predictive 
power, compared to the different volume doses. Error estimates of the maximum doses, i.e. 
the differences between planned and delivered maximum dose, is not explicitly given but 
could be expected to be relatively large. Both the definition of the end-point as well as the 
estimate of the delivered maximum dose should be regarded as limiting factors in this 
modeling and has highlighted the need for more high quality clinical data in the not-too-
distant future. 
 
3.7 WHOM SHOULD BE TREATED WITH SBRT FOR…. 
3.7.1 Local recurrence after prior SBRT with a new course for SBRT? 
Local failure is the most common type of failure observed post reirradiation with SBRT after 
prior SBRT161,162, motivating the indication of re-irradiation. However, in light of the 
reported high rate of serious toxicity from our material, there is a need to more carefully 
select suitable patients. A patient with a small relapsing peripherally located tumor and a long 
expected survival or even a chance for cure should be a candidate for re-irradiation. On the 
contrary, careful consideration should be taken for a patient with a big centrally located tumor 
with a short interval between the first treatment and relapse before re-irradiation is performed. 
A more complicated situation occurs when the relapsing tumor is threatening central 
structures. In these cases careful risk estimation between possible radiation induced side 
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effects and possible tumor induced symptoms has to be made as well as to consider other 
treatment options.  
3.7.2 Medically inoperable stage I NSCLC?  
This patient group has few treatment options and SBRT has emerged as an alternative with 
high rates of local control, limited side effects, on both long and short sight, and cancer 
specific survival at 5 years at 74%. Hence, SBRT for these patients remains a good and 
plausible treatment option and the question here is mainly to identify patients with limited 
survival due to other causes and patients at risk for high-grade side effects. As discussed 
previously, severe COPD, low pulmonary function and old age, should isolated not preclude 
a patient from curative intended SBRT. Instead, to further optimize the basis for treatment 
decision there is a need to create multi-dimensional-models, based on both dosimetric and 
patient characteristics, to foresee toxic effects, survival and disease control.  
3.7.3 Apically located lung tumors? 
With respect to RIBP, apically located lung lesions can be reasonably safely treated as long 
as the brachial plexus is considered a risk organ that needs careful assessment and accurate 
delineation. Improving the skills of radiation therapists in delineating the structure is of major 
importance since sparing of the structure should not unrightfully compromise with coverage 
of the target, leading to local failure. The NTCP-model predicts <10% probability of grade 2-
3 RIBP if D,max ≤30Gy for three fractions. However, paying attention to the distribution of 
dose within the plexus as well as to further address the utility of risk adapted SBRT are 
important future aspects. Today, an apical location of a lung lesion should therefore not 
exclude a patient from SBRT, but given the results from study IV, it is advisable to restrict 
Dmax ≤30Gy for a three-fraction-treatment.  
3.7.4 Adrenal metastasis?  
Adrenal metastases can be treated with excellent local control, but in light of the recorded 
toxicity and the limited survival of the patients as seen in study III, there is a need to 
distinguish favorable tumor- and patient characteristics for these patients. In terms of tumor 
characteristics, small tumor volume and right sided location seem favorable, the protective 
effect of the liver causing the major GI-OAR, the duodenum, only rarely being affected by 
the high-dose region. Additionally, to evaluate the overall treatment effect in comparison to 
the risk for side effects, the patient´s general status and the spread of the disease also be taken 
into consideration. With respect to both the risk of toxicity and the possible gain in overall 
treatment effect, the best patient is suggested to have limited metastatic spread and a small 
right-sided tumor located > 1cm from a GI-OAR. Most importantly, the aim should be to 
deliver an ablative dose with good dose coverage of the target and to keep current dose 
constraint guidelines for relevant OAR.
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4 FUTURE PERSPECTIVES 
Given the high performance of SBRT, there are a number of possibilities for further 
developing this method in order to broaden its long-term implications.  
First, local control is important and one question is whether further increasing the doses to the 
target will result in a clinical detectable increase in local control. Investigating this question 
with the highest scientific quality standards, such as in a randomized controlled trial, calls for 
very large patient material to ascertain and show if any of the observed difference is 
statistically significant or not. Nevertheless, a study comparing different dose-levels in 
relation to tumor size would be of enormous interest. Increasing the dose to larger tumors for 
a gain in local control has to be balanced against the possible increase in toxicity. Another 
side of the same coin is whether or not reducing the dose to small tumors could reduce side 
effects, but maintain local control, which would be important for tumors in close relation to 
OAR.  
In addition, to carefully assess dose to OAR both retrospectively and prospectively to gain 
clinical data of side effects is of utmost importance in learning more about the risks of this 
treatment. At present, current dose constraints may be over- and/or underestimated. At the 
same time, it is important to further develop the modeling technique estimating the 
probability of complications. In addition to evaluating the impact of dose-volumetric data to 
explain toxicity, it is crucial to also incorporate clinical parameters in the prospective 
analyses. For the long-term perspective, the aim should also be to include information from 
biomarkers, predicting the individual radiosensitivity. This will include information of 
genetic polymorphism (SNPs) on genes important for the radiosensitivity of the individual, 
for tumors to provide the relevant genomic and proteomic profiles and information obtained 
by different imaging procedures.    
Moreover, treatment of metastatic patients is developing and the use of SBRT as an isolated 
treatment modality has to be reconsidered. Systemic agents with new mechanisms of action 
increase disease control, but do not always eradicate the entire macroscopic tumor volume. 
SBRT may in these cases be used as a consolidating treatment, converting a partial tumor 
response to a complete response. Theoretically, for patients where 2nd and 3rd line treatment 
normally has very limited effect, SBRT might in these situations improve survival and 
prolong time to progression substantially. Another situation appears when some cell clones of 
a tumor develop mechanisms to outwit the systemic medication, making the therapy less 
effective at a few tumor sites. In these situations SBRT may be used as local treatment to 
those sites, while maintaining or temporarily holding up the systemic agent, dependent on 
toxicity profile of the agent. This concept, with SBRT beyond progression, may lead to the 
extended use of low-toxic systemic therapy or to a “treatment rest” for a patient with high 
toxic systemic therapy. Both survival and quality of life could be substantially improved.  
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Last but not least, a very important aspect for the future is to understand the biological 
changes in the tumor, in the normal tissue and in the patient after SBRT. Therefore, clinical 
and pre-clinical studies have to be performed in an interdisciplinary way, analyzing findings 
from the laboratory bench as well as via clinical patient outcomes in order to link the results 
and data to one another.  
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5 POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ 
SVENSKA 
Stereotactic body radiation therapy (SBRT) är en strålbehandlingsteknik som uppfanns på 
1990-talet på Karolinska sjukhuset. Vid SBRT ges mycket höga stråldoser, under endast 3-5 
fraktioner, mot tumör samt minimal marginal av normalvävnad. Det bestrålade områdets 
funktion slås ut. Metoden är idag en standardbehandling för medicinsk inoperabel tidig icke-
småcellig lungcancer (NSCLC) och har spritts över hela världen tack vare mycket god lokal 
kontroll (>90%), låg grad av biverkningar samt den korta behandlingstiden vilket gör det 
bekvämt för patienten (behandling av tidig NSCLC med SBRT tar en vecka i jämförelse med 
ungefär sju veckor vid konventionell strålbehandling). Patienter med lungcancer som tidigare 
inte kunde opereras och endast fick konventionell behandling samt ofta hade återfall, kan nu 
botas.  
Projekt 1: Rebestrålning. I frånvaro av andra möjliga behandlingsalternativ har patienter på 
Karolinska sjukhuset pga lokal tumörprogress erhållit rebestrålning mot tidigare SBRT 
behandlade lungtumörer. Tjugonio patienter med 32 rebestrålade lungtumörer med olika 
ursprung analyserades i studien som framför allt syftade till att utvärdera biverkningar. 
Sammanlagt fick 11 patienter svåra biverkningar och riskfaktorer utgjordes av stor tumör, 
central lokalisation (dvs nära bronker, hjärta, kärl) och kort tid mellan första behandlingen 
och rebestrålningen. Sammantaget visar studien att rebestrålning av små tumörer perifert i 
lungan är en bra behandling, medan patienter med stora centralt belägna tumörer löper risk 
för svåra biverkningar.   
Projekt 2: Långtidsuppföljning av SBRT av tidig NSCLC. SBRT av lokaliserad 
medicinsk inoperabel NSCLC har visat mycket goda resultat med en lokal kontroll >90% vid 
3 år. I dagsläget finns dock begränsade data på långtidseffekterna efter behandlingen – 
tumörkontroll, sena biverkningar samt radiologiska och fysiologiska förändringar. Studie II är 
en långtidsuppföljning av en prospektivt insamlad patientgrupp (57 patienter) som tidigare 
analyserats med avseende på korttidseffekter5,6. Långtidsuppföljningen visar fortsatt god 
kontroll av den behandlade tumören (79% vid 5 år) och få biverkningar som uppkommer 
efter mer än 3 år efter behandlingen. Tyvärr ser man även att överlevnaden är begränsad i 
denna patientgrupp (30% vid 5 år), framför allt till följd av andra hjärt- och lung sjukdomar. 
Resultaten i denna studie stödjer den fortsatta användningen av SBRT för dessa patienter.   
Projekt 3: SBRT av binjuremetastaser. Binjuremetastaser är relativt vanliga och ger oftast 
inga symtom. Standardbehandling (lokalbehandling) utgörs av kirurgi, men alla patienter är 
inte lämpliga att operera och ett behandlingsalternativ är då SBRT. SBRT har dock inte 
utvärderats i tillräcklig omfattning på binjuremetastaser för att säkert fastställa att 
behandlingen gagnar patienten. I denna studie utvärderas den tumörbromsande effekten och 
ställs i relation till biverkningar hos patienten. Femtioåtta patienter med 62 binjuremetastaser 
från olika primärtumörer inkluderades från tre olika centra i Europa (Karolinska Stockholm, 
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VU-Medical Center Amsterdam, Rigshospitalet Köpenhamn). Tumörkontrollen var mycket 
god (82% vid 2 år), men vi noterade även att 12% av patienterna fick svåra biverkningar vilka 
framför allt utgjordes av symtom från mag-tarmkanalen. Sammantaget visar studien att man 
kan få mycket god tumörkontroll efter SBRT av binjuremetastaser, vilket dock måste vägas 
mot risken för biverkningar. Framtida studier behövs där man utrönar vilka specifika 
patientgrupper som kan ha större nytta av just den här behandlingen. 
Projekt 4: SBRT-inducerad nervskada på plexus brachialis vid behandling av tumörer 
belägna högt upp i lungan.Vid SBRT av tumörer högt upp i lungan kan ibland plexus 
brachialis – ett nervplexus som står för armens och handens funktion – vara ett riskorgan. Om 
stråldoserna mot detta nervplexus blir för höga kan patienten få smärta, känselstörningar och 
svårigheter att röra arm och hand. Risken för denna biverkan måste dock ställas mot risken 
för att underbehandla tumören vilket kan orsaka tumörtillväxt som i sin tur ger lokala skador 
på plexus med mycket svårbehandlade nervsymtom. I dagsläget är det oklart hur mycket 
strålning dessa nerver tål vid SBRT. Studie IV är en retrospektiv studie av 57 patienter med 
61 tumörer i övre delen av lungan. Sju av dessa patienter utvecklade symtom på 
strålinducerad plexusskada (RIBP). Utifrån dessa data skapade vi en modell för att uppskatta 
risken för RIBP vid SBRT och vi analyserade fram en maxdos till plexus brachialis (30Gy på 
3 fraktioner) som man inte bör överstiga. Vid tolkning av en sådan modell bör man dock ha i 
åtanke att det även finns andra faktorer (individuell strålkänslighet, andra mediciner, tidigare 
strålbehandlingar etc) som kan påverka risken för att utveckla denna biverkan. 
Sammantaget stödjer resultaten i denna avhandling SBRT som fortsatt behandlingsmetod. 
Det finns dock flera områden att vidareutveckla t.ex. frågan om dosökning till olika tumörer 
liksom frågan om kombinationsbehandling med SBRT och systemiska behandlingar. Vidare 
behöver man analysera effekten av olika doser till såväl tumör som till normalvävnad och 
relatera detta till såväl kliniska symtom till prekliniska resultat. 
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